HELP Copays Act

Reported lobbying issue

Health Issues: HR 5509/S.2903 Safe Step Act HR 6423/S. 864 HELP Copays Act

Reported lobbying issue

Medicare/Medicaid: Issues related to reimbursement for hemophilia services and treatments in Medicare Issues related to reimbursement for hemophilia services and treatments in Medicaid Implementation of H.R. 1, One Big Beautiful Bill Act Implementation of Medicaid Community Engagement requirements Insurance: Implementation of H.R. 1, One Big Beautiful Bill Act Affordable Care Act implementation Coverage of hemophilia treatments and services in private insurance plans Policies related to co-pay accumulators, including the HELP Copays Act (S 864, HR 6423) Policies related to the operations of pharmacy benefits managers: comments on proposed rules re PBM transparency (EBSA-2026-0001) and prior authorization for prescription drugs (CMS-0062-P). Private insurance policies that discriminate coverage for high-cost drugs and use of patient assistance programs, also known as Alternative Funding Programs Pharmacy: Issues related to participation in the 340B Drug Discount Program Polices related to PBMs and drug cost transparency 340B Drug Pricing Integrity and Affordability for Patients Act discussion draft SECURE 340B Act, HR 9599 Budget/Appropriations: Funding for federal hemophilia programs at CDC and HRSA for FY27 Funding and staffing for the CDC Division of Blood Disorders and Public Health Genomics

Reported lobbying issue

Health Issues: 340B: Biologic/Small molecule drug negotiation eligibility within HR 7174/S.832 EPIC Act; CDC Type 1 Diabetes Awareness and Education within LHHS appropriations; Clinical Trial Diversity; Clinical Trial Data Requirements in AG Appropriations Bill; Copay Accumulators; COPD Education and Awareness within LHHS appropriations; COPD Research Funding within LHHS appropriations; Delinking; Drug Pricing - General; Drug Price Negotiations within Inflation Reduction Act; Drug Pricing- General Issues; FDA Drug Development; FDA Issues - General; Issues related to HR 1 One Big Beautiful Bill; HR 6423/S864 HELP Copays Act; HR 2880: Protecting Patients Against PBM Abuses Act; HR 5376:Inflation Reduction Act; HRSA - Type 1 Diabetes Screening within LHHS appropriations; Influenza Vaccines; Insurance Design/Utilization Management; Intellectual Property; International Reference Pricing; Most Favored Nation; Orphan Drug Negotiation within HR 5539/S 3131 Orphan Cures Act; Out of Pocket Cap; Pandemic and All-Hazards Preparedness Act (PAHPA) Reauthorization; Patient Experience/Patient Focused Drug Development within the FDA/AG Appropriations; Pharmacy Benefit Managers (PBM) Reform; Rare Pediatric Priority Review Voucher Program Reauthorization within HR 7834; Rebate Pass Through; Respiratory Syncytial Virus (RSV) Access; Routine Immunization Rates; S. 864 HELP Copays Act: S. 1339 (118th): PBM Reform Act; S. 1375: HELP Copays Act; S. 1542 (118th) DRUG Act; S. 2027: Prescription Information Modernization Act; S.4504 / HR 8698 (118th): SCREEN for Type 1 Diabetes Act; Supply Chain; Tax Credits; Transplant; Vaccine Injury Compensation Program; Vaccines-General Issues. Medicare/Medicaid: 340B; Medicare Negotiation, and Most Favored Nation. Trade (domestic/foreign): COINS Act Implementation; HR 9102 BINSA Bill; Supply Chain Issues; and Importation issues. Taxation/Internal Revenue Code: Supply Chain issues; TRIP Waivers; and Vaccine Injury Compensation Program. Copyright/Patent/Trademark: S. 43: Skinny Labels, Big Savings Act; S. 2276 ETHIC Act; and Intellectual Property. Manufacturing: Insulin; Pharmacy Benefits Managers (PBMs); Taxes- General Issues; China issues; Type 1 Diabetes Screening; and Vaccines - General Issues

Reported lobbying issue

Health Issues: FY 2027 Funding for medical research at the NIH and CDC FY 2027 Appropriations - DoD Congressionally Directed Medical Research Program S 864/ HR 6423 Help Ensure Lower Patient Copays Act S 526 Pharmacy Benefit Manager Transparency Act HR 5509/ S 2903: Safe Step Act S 3304 / HR 5684 Medical Foods and Formula Access Act CMS - Interoperability Standards and Prior Authorization for Drugs proposed rule CMS - RFI on step therapy in Medicare CMS - Reimbursement for infused biosimilars CMS - Medicare Competitive bidding for ostomy supplies FDA - Approvals for pediatric IBD medications HHS - FY 2027 NBPP

Reported lobbying issue

Medicare/Medicaid: Issues related to reimbursement for hemophilia services and treatments in Medicare Issues related to reimbursement for hemophilia services and treatments in Medicaid Implementation of H.R. 1, One Big Beautiful Bill Act Insurance: Implementation of H.R. 1, One Big Beautiful Bill Act Affordable Care Act implementation Coverage of hemophilia treatments and services in private insurance plans Policies related to co-pay accumulators, including the HELP Copays Act (S 864, HR 6423) Private insurance policies that discriminate coverage for high-cost drugs and use of patient assistance programs, also known as Alternative Funding Programs Policies related to the extension of enhanced advanced premium tax credits, including HR 247, HR 1, HR 5371, S 46, HR 1834 Pharmacy: Issues related to participation in the 340B Drug Discount Program Polices related to PBMs and drug cost transparency Budget/Appropriations: Funding for federal hemophilia programs at CDC and HRSA for FY26 Funding for federal hemophilia programs at CDC and HRSA for FY27

Reported lobbying issue

Health Issues: 340B: Biologic/Small molecule drug negotiation eligibility within HR 7174/S.832 EPIC Act; CDC Type 1 Diabetes Awareness and Education within LHHS appropriations; Clinical Trial Diversity; Copay Accumulators; COPD Education and Awareness within LHHS appropriations; COPD Research Funding within LHHS appropriations; Delinking; Drug Pricing - General; Drug Price Negotiations within Inflation Reduction Act; Drug Pricing- General Issues; FDA Drug Development; FDA Issues - General; Issues related to HR 1 One Big Beautiful Bill; HR 6423/S864 HELP Copays Act; HR 2880: Protecting Patients Against PBM Abuses Act; HR 5376:Inflation Reduction Act; HRSA - Type 1 Diabetes Screening within LHHS appropriations; Influenza Vaccines; Insurance Design/Utilization Management; Intellectual Property; International Reference Pricing; Most Favored Nation; Orphan Drug Negotiation within HR 5539/S 3131 Orphan Cures Act; Out of Pocket Cap; Pandemic and All-Hazards Preparedness Act (PAHPA) Reauthorization; Patient Experience/Patient Focused Drug Development within the FDA/AG Appropriations; Pharmacy Benefit Managers (PBM) Reform; Rare Pediatric Priority Review Voucher Program Reauthorization within HR 7834; Rebate Pass Through; Respiratory Syncytial Virus (RSV) Access; Routine Immunization Rates; S. 864 HELP Copays Act: S. 1339 (118th): PBM Reform Act; S. 1375: HELP Copays Act; S. 1542 (118th) DRUG Act; S. 2027: Prescription Information Modernization Act; S.4504 / HR 8698 (118th): SCREEN for Type 1 Diabetes Act; Supply Chain; Tax Credits; Transplant; Vaccine Injury Compensation Program; Vaccines-General Issues. Medicare/Medicaid: 340B; Medicare Negotiation, and Most Favored Nation. Trade (domestic/foreign): Supply Chain Issues; and Importation issues. Taxation/Internal Revenue Code: Supply Chain issues; TRIP Waivers; and Vaccine Injury Compensation Program. Copyright/Patent/Trademark: S. 43: Skinny Labels, Big Savings Act; S. 2276 ETHIC Act; and Intellectual Property. Manufacturing: Insulin; Pharmacy Benefits Managers (PBMs); Taxes- General Issues; Type 1 Diabetes Screening; and Vaccines - General Issues

Reported lobbying issue

Medicare/Medicaid: Issues related to reimbursement for hemophilia services and treatments in Medicare Issues related to reimbursement for hemophilia services and treatments in Medicaid H.R. 1, One Big Beautiful Bill Act Insurance: H.R. 1, One Big Beautiful Bill Act Affordable Care Act implementation Coverage of hemophilia treatments and services in private insurance plans Policies related to co-pay accumulators, including the HELP Copays Act (S 864, HR 6423) Private insurance policies that discriminate coverage for high-cost drugs and use of patient assistance programs, also known as Alternative Funding Programs Policies related to the extension of enhanced advanced premium tax credits, including HR 247, HR 1, HR 5371, S 46, HR 1834. Pharmacy: Issues related to participation in the 340B Drug Discount Program SUSTAIN 340B ACT - Draft Senate 340B reform legislation Polices related to PBMs and drug cost transparency Budget/Appropriations: Funding for federal hemophilia programs at CDC and HRSA for FY26

Reported lobbying issue

Budget/Appropriations: H.R. 1: One Big Beautiful Bill Act (Public Law 119-21) H.R. 4: Rescissions Act of 2025 (Public Law 119-28) H.R. 4121: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 8646: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 S.___: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 H. Res. 566: Providing for consideration of the Senate amendment to the bill (H.R. 1) to provide for reconciliation pursuant to title II of H. Con. Res. 14 H.R. 9310: Department of Homeland Security Appropriations Act, 2027 S. 2256: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 S. 2587: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 9260: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 S.___: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 H.R. 5342: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 H.R. 6938: Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriations Act, 2026 (Public Law 119-74) H.R. 8845: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027 S.___: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027 S. 2354: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 H.R. 5371: Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (Public Law 119-37) S. 1071: National Defense Authorization Act for Fiscal Year 2026 (Public Law 119-60) S. 2296: National Defense Authorization Act for Fiscal Year 2026 H.R. 8800: National Defense Authorization Act for Fiscal Year 2027 S. 4784: National Defense Authorization Act for Fiscal Year 2027 S. 2: Secure America Act (Public Law 119-18) H.R. 7148: Consolidated Appropriations Act, 2026 (Public Law 119-75) Presidents Budget Fiscal Year 2027 Inflation Reduction Act of 2022 (Public Law 117-169) implementation policy issues Government funding policy issues Copyright/Patent/Trademark: S. 43: Skinny Labels, Big Savings Act S. 1040: Drug Competition Enhancement Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 1546: Patent Eligibility Restoration Act of 2025 (PERA) S. 1553: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) S. 2276: Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 2620: REMEDY Act S. 2658: Medication Affordability and Patent Integrity Act S. 3452: Biological Intellectual Protection Act of 2025 H.R. 890: Stopping Pharmas Ripoffs and Drug Savings For All Act H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) H.R. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) H.R. 4570: Interagency Patent Coordination and Improvement Act of 2025 H.R. 6485: Skinny Labels, Big Savings Act H.R. 6624: Biological Intellectual Property Protection Act of 2025 Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues AI patent policy issues Patent eligibility policy issues Post-grant proceeding policy issues Patent submission policy issues Patent fee policy issues Health Issues: S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 1387: National Biotechnology Initiative Act of 2025 S. 1414: Expedited Access to Biosimilars Act S. 1954: Biosimilar Red Tape Elimination Act S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) S. 2658: Medication Affordability and Patent Integrity Act S. 3014: Ensuring Timely Access to Generics Act of 2025 S. 3345: PBM Price Transparency and Accountability Act S. 3788: CLEAR LABELS Act H.R. 1: One Big Beautiful Bill Act (Public Law 119-21) H.R. 946: ORPHAN Cures Act H.R. 1262: Mikaela Naylon Give Kids a Chance Act H.R. 1492: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 2214: DRUG Act H.R. 3521: Clinical Trial Modernization Act H.R. 4317: PBM Reform Act of 2025 H.R. 5256: 340B ACCESS Act H.R. 6423: HELP Copays Act H.R. 6610: Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act] H.R. 7837: Most Favored Patients Act H.R. 7953: FAIR ACT H.R. 8269: CLEAR LABELS Act H.R. 9661: Expedited Access to Biosimilars Act Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) 340B Drug Pricing Integrity and Affordability for Patients Act (draft) SECURE Act of 2026 (draft) Biopharmaceutical innovation policy issues User fee issues Vaccine policy issues Inflation Reduction Act of 2022 (Public Law 117-169) implementation policy issues IRA price negotiation expansion policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Most Favored Nation (MFN) policy issues Drug importation policy issues FDA policy issues Competition policy issues Orphan Drug Act policy issues Antimicrobial resistance policy issues Compounding policy issues Supply chain policy issues Clinical trial policy issues 340B drug discount program rebate and policy issues 340B rebate pilot program Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues Artificial intelligence policy issues Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Executive Order: Lowering Drug Prices by Once Again Putting Americans First Medicare/Medicaid: H.R. 1: One Big Beautiful Bill Act (Public Law 119-21) Inflation Reduction Act of 2022 (Public Law 117-169) implementation policy issues Part D redesign and policy issues including non-interference and rebates policy issues Part B policy issues Drug cost and pricing policy issues Medicare rebate policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues CMS IPAY Guidance on the Medicare Drug Price Negotiation Program IPAY and Maximum Fair Prices policy issues Medicaid rebate policy issues GENErating cost Reductions for U.S. Medicaid (GENEROUS) model Global Benchmark for Efficient Drug Pricing (GLOBE) Proposed Rule Guarding U.S. Medicare Against Rising Drugs Costs (GUARD) Proposed Rule Trade (domestic/foreign): Proclamation: Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States (April 2, 2026) S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) H.R. 4780: USTRx Act H.R. 6089: Biomanufacturing Excellence Act of 2025 H.R. 9102: Biotech Investment National Security Act of 2026 (BINSA) H.R. 9142: Prohibiting Adversarial Patents Act of 2026 (PAPA) Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Tariff policy issues Most Favored Nation (MFN) policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues COINS Act implementation policy issues China outbound investment policy issues including COINS Act US-UK Framework Agreement

Reported lobbying issue

Budget/Appropriations: Funding for federal hemophilia programs in FY27 House and Senate Labor-HHS Appropriations bills NIH FY27 appropriations Pharmacy: Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing program 340B Drug Pricing Integrity and Affordability for Patients Act discussion draft Medical/Disease Research/Clinical Labs: Hemophilia research, prevention, surveillance and service programs and issues; advancing care for women and girls with bleeding disorders Medicare/Medicaid: Implementation of H.R. 1, One Big Beautiful Bill Act Reimbursement for hemophilia services and treatments in Medicare Reimbursement for hemophilia services and treatments in Medicaid Preserving and expanding access to Medicaid Implementation of Medicaid Community Engagement requirements Issues related to 1115 of the Social Security Act; policies related to work requirements in Medicaid Health Issues: Blood and plasma safety and awareness Bleeding disorders awareness Fostering Effective Diagnosis and Treatment for Underserved Populations (FED UP) with Bleeding Disorders Act (H.R. 8794) Insurance: Implementation of H.R. 1, One Big Beautiful Bill Act Implementation of the Affordable Care Act The HELP Copays Act (S. 864, H.R. 6423) Coverage of hemophilia treatments and services in private insurance plans, including the alternative funding model Policies related to copay accumulator adjustor and maximizer programs Policies related to the operations of pharmacy benefits managers: comments on proposed rules re PBM transparency (EBSA-2026-0001) and prior authorization for prescription drugs (CMS-0062-P)

Reported lobbying issue

Budget/Appropriations: -Labor, Health and Human Services, Education and Related Agencies Appropriations Act, 2027, support funding for epilepsy programs and research including $11.581 billion for the CDC including $11.5 million for the CDCs Epilepsy program and $164 million for the CDCs Safe Motherhood and Infant Health Program; language supporting a report about establishing a National Plan for Epilepsy; at least $51.3 billion for the NIH and $468 million for the BRAIN Initiative; increased funding for the Social Security Administration; and language supporting a report about how the newborn screening evidence-based review process will continue to be implemented and language clarifying that Title V can fund state-sponsored genetic screening pilot programs. -Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2027, support at least $29 million for the VA Epilepsy Centers of Excellence. -Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Act, 2027, support robust funding for the Food & Drug Administration -Defense Appropriations Act, 2027, within the Congressionally Directed Medical Research Programs, support $12 million for the Epilepsy Program, $12 million for the Tuberous Sclerosis Complex program and $175 million for the TBI and Psychological Health Program. Health Issues: -P.L. 119-21, Support policies and processes that reduce the impact of the cuts and changes to Medicaid on people with serious and chronic conditions, people with disabilities, and caregivers -Budget Reconciliation Packages, oppose additional cuts to Medicaid -S. 494/H.R. 1189, National Plan for Epilepsy Act, support passage -Requests to join the Congressional Epilepsy Caucus -S. 2903/H.R. 5509, Safe Step Act, support passage -S. 864/H.R. 6423, HELP Copays Act, support passage -WISeR Model, express concern with how it could impede access to some epilepsy treatments -PBM Reform, support legislative and regulatory policies on PBM reform and the inclusion of patient-centric policies -Medicare Part Ds Six Protected Classes policy, support coverage of and access to all epilepsy treatments and express concerns with the impact of the GUARD Model on the Six Protected Classes policy. -ACA marketplace rule, express concerns that changes will decrease enrollment and increase costs -Telehealth, support extensions of telehealth flexibilities including the prescribing of epilepsy medications that are controlled substances -S. 1024/H.R. 2151, Seizure Awareness and Preparedness Act, support passage -U.S. Department of Health and Human Services (HHS), support protecting the current structure of HHS and express concerns with HHS staffing changes and cuts -NIH, support the current structure, current facilities and administrative cost structure, and grantmaking process of the NIH; express concerns with leadership and staffing changes and an expansion of multiyear funding -Support programs that assist caregivers -Oppose legislative or regulatory policies that rely on metrics like Quality-Adjusted Life Years -Support rescheduling and safe and legal access to medical cannabis -S. 1816/ H.R. 3514, Improving Seniors Timely Access to Care Act, support passage -Express concerns with legislative and regulatory policies that would restrict the use of animals in research -Support legislation and policy preserving charitable giving including the Combined Federal Campaign -H.R. 6280, Access to Genetic Counselor Services Act, support passage -S. 4440, Clinical Trial Modernization Act, support passage -Support legislation and regulations that protect Medicaid Home- and Community-Based Services (HCBS) and increase access to these services -Prescription Drug User Fee Act Reauthorization, support priorities for the rare disease community -Fiscal Year 2027 Hospital Inpatient Prospective Payment Systems Proposed Rule, oppose proposals to repeal the alternative pathway for new technology add-on payments for breakthrough devices and eliminate the hospital outpatient prospective payment system device pass-through payments Civil Rights/Civil Liberties: -FAA reauthorization, support implementation of disability provisions -Surface Transportation Reauthorization, support inclusion of disability and accessibility provisions -Autonomous vehicle legislation, support the inclusion of disability and accessibility provisions -Supported temporary exemptions to NHTSA safety requirements to test autonomous vehicles Education: -Department of Education, oppose Reductions of Force at and changes to (including moving sections of) the Dept. of Education that could impede the rights of students with disabilities -S. 3448/H.R. 6617, Keeping All Students Safe Act, support passage

Reported lobbying issue

Health Issues: Access to Care One Big Beautiful Bill, P.L. 119-21. Advocate to protect cancer patients in implementation of changes to Medicaid under the law. Health Care Affordability Act, H.R.247, S.46. Bill would permanently extend the enhanced Affordable Care Act tax credits. Association Health Plans Act, H.R.2528, S.1847. This bill would amend the Employee Retirement Income Security Act of 1974 to treat association health plans as employers. Self-Insurance Protection Act, H.R. 2571. This bill would amend the Employee Retirement Income Security Act of 1974 to exclude from the definition of health insurance coverage certain medical stop-loss insurance. Access to Breast Cancer Diagnosis Act, H.R. 3037/S.1500. To amend title XXVII of the Public Health Service Act to prohibit group health plans and health insurance issuers offering group or individual health insurance coverage from imposing cost-sharing requirements with respect to diagnostic and supplemental breast examinations. Women and Lung Cancer Research and Preventative Services Act of 2025, H.R.2319, S.1157. This bill requires the Department of Health and Human Services working with the Department of Defense, to conduct an interagency review to evaluate the status of and identify opportunities for research on women and lunch cancer preventative services. Safe Step Act, H.R. 5509, S. 2903. Bill would require an exceptions process for any medication step therapy protocol in commercial insurance plans. Bipartisan Premium Tax Credit Extension Act, H.R. 5145, Bill would extend the enhanced ACA tax credits for one year. Breaking the Gridlock Act, H.R. 1834. Bill would extend the enhanced Affordable Care Act tax credits for three years. Common Ground for Affordable Health Care Act, H.R.6575. Bill would extend the enhanced Affordable Care Act tax credits for one year and make other adjustments. Bipartisan Health Insurance Affordability Act, H.R.6501. Bill would extend the enhanced Affordable Care Act tax credits for two years and make other adjustments. Medically Tailored Home-Delivered Meals Demonstration Pilot Act, H.R.5439, S.2834. The bill would create a pilot program in Medicare for beneficiaries with diet-related diseases to receive medically tailored meals to their own home. Womens Health and Cancer Rights Modernization Act of 2025, H.R.5813. This bill amends the Womens Health & Cancer Rights Act to require that commercial health plans provide coverage of breast or wall reconstruction provided as part of breast cancer treatment. HELP Copays Act, H.R. 6423, S. 864. Bill would apply financial assistance towards the cost-sharing requirements of health insurance plans. Lung Cancer Screening and Prevention Act, H.R.1406. To amend title XVIII of the Social Security Act to authorize the coverage of additional lung cancer screening tests under the Medicare program. Mobile Cancer Screening Act, H.R. 4417, S. 2927. The bill would award grants, contracts, or cooperative agreements for supporting new mobile cancer screening units to expand patient access to essential screening services in rural and underserved communities. Breast Cancer Research Stamp Reauthorization Act of 2026, H.R.8358, S.4318. This bill would allow the U.S. Postal Service to extend its authority to issue the Breast Cancer Research semipostal stamp for 10 more years to raise funding for breast cancer research. Recognizing April as Cancer Prevention and Early Detection Month, H.Res.1196. The resolution would uplift the national commitment to cancer prevention and early detection to reduce the cancer burden and improve health outcomes for all Americans. Womens Health and Cancer Rights Modernization Act of 2025, H.R.5813. This bill would require group health plans and health insurers offering group or individual health insurance coverage to cover specified breast or chest wall reconstruction services related to breast cancer treatment. Medical Records Access Fairness Act, H.R.7790. The bill would require health care providers to give patients free access to their medical records at least once a year. Knock Out Cancer Act (H.R. 3873, or KO Cancer Act). The will would boost National Cancer Institute funding by 25% annually for FY2026-2030 to match cancers mortality toll and direct a report on drug shortages. Health Disparities Screening for Communities to Receive Early and Equitable Needed Services (SCREENS for Cancer Act, H.R. 2381, S.1866. Reauthorizes the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) through 2030 to provide the program greater flexibility in providing access to lifesaving screening, diagnostic, and treatment services and continue its innovative work aimed to reduce disparities and advance health equity in breast and cervical cancer. Education and Awareness Requires Learning Young (EARLY) Act, H.R. 4541, S. 2339. This bill would reauthorize the CDC program that supports young and high-risk women as well as their providers to better understand breast health. Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act, H.R. 1300, S. 297. Legislation to remove cost sharing of PSA testing for those at the highest risk of being diagnosed with prostate cancer. Lung Cancer Screening and Prevention Act, H.R.1406. To amend title XVIII of the Social Security Act to authorize the coverage of additional lung cancer screening tests under the Medicare program. Data Equity. Legislative and regulatory funding to support the collection of detailed demographic data toward reducing disparities in cancer prevention, detection, and treatment. Prevent HPV Cancer Act of 2025, H.R. 6561. This bill would create a national public awareness campaign to promote education and awareness of HPV and HPV-associated cancers and would increase funding for the NBCCED program to boost breast and cervical cancer screening. Health Equity and Accountability Act. This bill advances policies to reduce health disparities and improve cancer prevention, research, and care for underserved communities. Childhood Cancer Childhood Cancer Survivorship, Treatment, Access, and Research Reauthorization Act (STAR) Act. Continued implementation and funding of the Childhood Cancer STAR Act to promote the development of new, safer therapies for children with cancer. Our appropriations request includes $30 million for the Childhood Cancer STAR Act and $50 million for the Childhood Cancer Data Initiative. Accelerating Kids Access to Care Act, P.L. 119-75. Legislation that alleviates these burdens for families and providers by facilitating coordination across state lines and clarifying the process by which state Medicaid programs can cover specialized treatment regardless of where the child lives and where their care is received. Give Kids and Chance Act of 2025, P.L. 119-75. Legislation that would accelerate pediatric cancer treatments and expand access to live-saving therapies for children battling rare diseases, spur drug development for pediatric rare diseases, improve outcomes for patients, and close gaps in pediatric drug research. One Big Beautiful Bill, P.L. 119-21, Advocate to protect pediatric cancer patients in implementation of changes to Medicaid under the law. Quality of Life Palliative Care Palliative Care and Hospice Education and Training Act (PCHETA), S. 22870, H.R. 4425. Legislation to facilitate access to palliative care and coordinated care management. Palliative Care Research Funding. Funding to focus and expand national research programs in palliative care at the National Institutes of Health. Specifically, ACS CAN is working to include funding for palliative care research in the FY26 LHHS Appropriations bill. Lainie Jones Comprehensive Cancer Survivorship Act, H.R. 8839. The bill would create pathways to address the financial challenges of cancer survivorship and maintain patients access to the health services needed to address the long-term effects of cancer. Federal Health Care Programs Department of Defense Cancer Research Funding. Ensure continued funding for cancer research within the DOD's Congressionally Directed Medical Research Program. Clinical Trials Clinical Trial Modernization Act, H.R. 3521, S. 4440. Increase access to clinical trials for all persons with cancer to participate by reducing barriers to enrollment including support for and remote access to trials. To amend the Internal Revenue Act of 1986 to exclude from gross income certain compensation to clinical trial participants, and for other purposes, H.R. 4184. Legislation to amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants. Taxation/Internal Revenue Code: One Big Beautiful Bill Act, P.L.119-21. Advocate to protect cancer patients in implementation of changes to Medicaid under the law. Issues regarding expanding the availability of the charitable deduction for non-itemizers. Issues respecting charitable giving and life income planning, issues regarding taxation of charitable organizations, and issues regarding economic relief for nonprofit organizations. Issues related to stimulus for nonprofit organizations and increasing charitable giving. Clinical Trial Modernization Act, H.R. 3521, S. 4440. Increase access to clinical trials for all persons with cancer to participate by reducing barriers to enrollment including support for ancillary (non-medical) costs and remote access to trials. To amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants, and for other purposes, H.R. 4184. Legislation to amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants. Health Care Affordability Act, H.R. 247, S. 46. Bill would permanently extend the enhanced Affordable Care Act tax credits. Bipartisan Premium Tax Credit Extension Act, H.R. 5145. Bill would extend the enhanced ACA tax credits for one year. Breaking the Gridlock Act, H.R. 1834. Bill would extend the enhanced Affordable Care Act tax credits for three years. CommonGround for Affordable Health Care Act, H.R.6575. Bill would extend the enhanced Affordable Care Act tax credits for one year and make other adjustments. Bipartisan Health Insurance Affordability Act, H.R.6501. Bill would extend the enhanced Affordable Care Act tax credits for two years and make other adjustments. A bill to amend the Internal Revenue Code of 1986 to extend the temporary enhanced premium credits, S.2824. Bill would extend the enhanced ACA tax credits for two years. Charity Parity Act, H.R. 8783, S. 4511. The bill would allow taxpayers to make direct qualified charitable distributions (QCDs) from their employer sponsored retirement plans. Tobacco: Issues relating to smoking cessation, age of sale of tobacco products, tobacco taxes, graphic warning labels, product regulation, and smoke-free environments.; Issues relating to FDA regulation of flavors, electronic cigarettes and cigars. Strengthening Task Force Operations to Prevent Illicit Vaping Act (STOP Illicit Vaping Act), H.R.6845, / S.3569, Bill would codify and strengthen the federal multi-agency task force, led by the Department of Justice and Food and Drug Administration, to coordinate enforcement, information sharing, and strategy to combat the illegal importation, distribution, and sale of unauthorized e-cigarettes. Increasing Access to Lung Cancer Screening Act, H.R.6178. This legislation provides coverage without cost-sharing for lung cancer screening and tobacco cessation to those on Medicaid and codifies existing lung cancer screening requirements and eliminates prior authorization for those on Medicare and private insurance. Helping Tobacco Users Quit Act, S. 2064. This bill provides for coverage of certain tobacco cessation services, without cost-sharing, of diagnostic, therapy, and counseling services and pharmacotherapy, including prescription and nonprescription tobacco cessation agents, that are provided under medical supervision and in accordance with specified guidelines under Medicaid and Children's Health Insurance Program (CHIP). Budget/Appropriations: One Big Beautiful Bill Act, P.L.119-21. Advocate to protect cancer patients in implementation of changes to Medicaid under the law. FY26 Labor, Health, and Human Services funding provisions. ACS CAN advocated for full implementation of the law and for funding to be issued consistent with statute. FY27 House and Senate Labor, Health and Human Services legislation. ACS CAN advocates for increases in cancer research and prevention, including NIH, NCI, CDC DCPC, and OSH funding. FY25 Defense Appropriations for cancer programs with CDMRP. ACS CAN advocates for cancer research funding within CDMRP and funding for the Initiative for Improving Native American Cancer Outcomes through NCIs coordination with NIMHD. FY27 Defense Appropriations for cancer programs with CDMRP. ACS CAN advocates for cancer research funding within CDMRP. ACS CAN advocates for increases in programs that advance research for cancers include the Peer Reviewed Cancer Research Program (PRCRP). FY27 Interior Appropriations for Indian Health Services funding. ACS CAN advocates for increased funding for health with a focus on cancer funding. FY27 Agriculture and FDA Appropriations for issues related to drug shortages and tobacco. ACS CAN advocates for funding for the FDA, for provisions to address drug shortages, and on tobacco policy including issues related to the FDA regulation of flavors, electronic cigarettes, and cigars and cessation therapies as well as language to reduce drug shortages and fully implement FDORA. Indian Programs Advance Appropriations Act of 2025, S. 2771, H.R. 5328. The bill would provide advance appropriations authority for certain accounts of the Bureau of Indian Affairs and Bureau of Indian Education of the Department of the Interior and the Indian Health Service. OMBs proposed Regulation for Federal Financial Assistance (May 2026). The changes in federal regulations would risk politicizing federal grant awards by empowering appointees to override scientific merit reviews, delaying cancer research progress, reducing transparency, and threatening NIH/CDC-funded breakthroughs that save lives. Medicare/Medicaid: One Big Beautiful Bill Act, P.L.119-21. Advocate to protect cancer patients in implementation of changes to Medicaid under the law. Lung Cancer Screening and Prevention Act, H.R. 140. To amend title XVIII of the Social Security Act to authorize the coverage of additional lung cancer screening tests under the Medicare program. Accelerating Kids Access to Care Act, P.L. 119-75. Legislation that alleviates these burdens for families and providers by facilitating coordination across state lines and clarifying the process by which state Medicaid programs can cover specialized treatment regardless of where the child lives and where their care is received. Ensuring Access to Essential Providers Act, S.2793. Bill would require Medicare Advantage plans to cover items and services furnished by certain essential community providers. Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, H.R. 5269, S. 2761. Bill would address Medicare reimbursement of laboratory services. Access to Genetic Counselor Services Act, H.R.6280. Bill would expand coverage of genetic counseling services under Medicare. Lung Cancer Screening and Prevention Act of 2025, H.R. 1406. This bill authorizes Medicare coverage of additional types of lung cancer screening tests that are approved by the FDA, regardless of whether they are recommended by the United States Preventive Services Task Force (USPSTF). Increasing Access to Lung Cancer Screening Act, H.R.6178. This legislation provides coverage without cost-sharing for lung cancer screening and tobacco cessation to those on Medicaid and codifies existing lung cancer screening requirements and eliminates prior authorization for those on Medicare and private insurance. Medical/Disease Research/Clinical Labs: Clinical Trial Modernization Act, H.R. 3521, S. 4440. Increase access to clinical trials for all persons with cancer to participate by reducing barriers to enrollment, including support for ancillary (non-medical) costs. To amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants, and for other purposes, H.R. 4184. Legislation to amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants. Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, H.R. 5269, S. 2761. Bill would address Medicare reimbursement of laboratory services. Asal Sayas National Strategy on Young Adult Cancers Act, S. 4717: Directs the NIH to develop a comprehensive national strategy to address the alarming rise of cancers in adults ages 18 to 49. American Cures Act, S. 4494. This bill would permanently fund several federal agencies and programs that perform biomedical research. Defense: Defense Appropriations. ACS CAN advocates for cancer research funding within CDMRP. Indian/Native American Affairs: Issues relating to Indian Health Services and the Congressional Native American Caucus. FY27 appropriations for the Indian Health Service. ACS CAN advocates for full funding for FY27 and advanced appropriations to ensure American Indians and Alaska Natives have access to quality and affordable health care services. Indian Programs Advance Appropriations Act of 2025, S. 2771, H.R. 5328. The bill would provide advance appropriations authority for certain accounts of the Bureau of Indian Affairs and Bureau of Indian Education of the Department of the Interior and the Indian Health Service. FY27 appropriations for the Initiative for Improving Native American Cancer Outcomes under the NIMHD and NCI. ACS CAN advocates for the continuation of full funding for the program to support research, education, outreach, and clinical access related to cancer in Native American populations.

Reported lobbying issue

Welfare: H.R8490/S.4396 - Social Security Caregiver Credit Act - All provisions Aviation/Airlines/Airports: H.R.9373 - Air Carrier Access Amendments Act of 2026 - Provisions relating to remedies and enforcement mechanisms for air passengers with disabilities. Small Business: S.3971 - Small Business Innovation and Economic Security Act - Provisions relating to the extension and enhancement of the SBIR and STTR programs through 2031, introducing new research security requirements, expanded funding opportunities, administrative streamlining, improved commercialization support, and strengthened data collection to better support small business innovation Budget/Appropriations: H.R 4016 / S.2572 - Department of Defense Appropriations Act Requested the House and Senate Appropriations Defense Subcommittee provide at least $80 million for the ALS Research Program in fiscal year 2026 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials. H.R. 4121 / S.2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million authorized in the ACT for ALS Act (P.L. 1179-79) for research to speed the regulatory process for new ALS and rare disease therapies in fiscal year 2026. H.R. 5304 / S.2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $180 million for ALS research at NIH in fiscal year 2026 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75,000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $15 million to continue CDCs National ALS Registry and Biorepository in fiscal year 2026 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and biospecimens, and support research of ALS prevention in the military. H.R. 1 - One Big Beautiful Bill Act Discussions around the implementation of the bill to ensure the medically frail, SSDI beneficiaries and/or those with terminal illnesses do not need to recertify for Medicaid coverage. Health Issues: H.R. 8205/S.4472 - Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 - All provisions. H.R. 7779 - HEALTHY BRAINS Act - All Provisions H.R. 3864 - Protecting Health Care for All Patients Act of 2025 All provisions related to the banning of use of the quality-adjusted Life year valuation metric in coverage and payment determinations under federal health care programs. H.Res.449/S.Res 266 - Supports the designation of ALS Awareness Month - All Provisions. H.R.2560/S.830 - Lifespan Respite Care Reauthorization Act of 2025 - Provisions relating to amending the Public Health Service Act to extend funding for respite care through 2030 and broadening the definition of 'family caregiver' to include all unpaid individuals. Medicare/Medicaid: H.R. 7336/S.3763 - ALS Better Care Act - All provisions. H.R. 6423/S. 864 - HELP Copays Act -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. H.R. 4206 / S. 1261 - CONNECT for Health Act - Provisions related to permanent telehealth services in Medicare and interstate telehealth services. H.R. 2491 / S. 1227 - Alleviating Barriers for Caregivers (ABC) Act - All provisions. H.R. 2560 / S.830 - Lifespan Respite Care Reauthorization Act - All provisions H.R. 3514 / S. 1816 - Improving Seniors Timely Access to Care Act of 2025 All provisions relating to prior authorization usage under Medicare Advantage Plans. H.R. 6280/S. 3607- Genetic Counselor Services Act - All provisions H.R.2172/S.1058 - Preserving Patient Access to Home Infusion Act - All Provisions H.R.8375/S.4284 - Medicare Advantage Improvement Act of 2026 - Provisions related to expedited care authorizations, increased transparency and oversight, align coverage criteria with traditional Medicare, and strengthen beneficiary protections, in Medicare Advantage plans. H.R.8500 - Timely Access to Coverage Decisions Act of 2026 - All Provisions Veterans: H.R 1685 / S. 749 - Justice for ALS Veterans Act -- All provisions, including those extending Dependency and Indemnity Compensation payments to surviving spouses of veterans who die from ALS, regardless of how long a veteran had ALS prior to death. H.R. 6001 - Veterans with ALS Reporting Act - All provisions, including ALS prevention for the military and access to care for veterans living with ALS. H.R2055/S.611 - Caring for Survivors Act - All provisions. H.R.6047 - Sharri Briley and Eric Edmundson Veterans Benefits Expansion Act of 2026 - Provisions related to increases in dependency and indemnity compensation for surviving spouses of servicemembers with a 100% disabling condition. H.R.9237 - Take Care of Americas Veterans Act - Provisions in Sections 103 and 104 relating to Increases to dependency and indemnity compensation (DIC) for surviving spouses of veterans who had a 100% disabling condition AND changes to qualification for increased DIC payments for surviving spouses of veterans who pass from ALS regardless of how long they lived with the condition. S.3988 - Veterans STAND Act - Provisions relating to providing annual preventative health evaluations and increased access to assistive technologies for veterans with spinal cord injuries or disorders, with new reporting and consultation requirements to improve care and outcomes. Taxation/Internal Revenue Code: H.R.2036/S. 925 - Credit for Caring Act of 2025 - All provisions. H.R. 138/S.1565 - Lowering Costs for Caregivers Act - All provisions Clinical Trial Tax Credit (Draft legislation) - All provisions. H.R. 2320 - Mobility Means Freedom Tax Credit Act - All provisions Pharmacy: H.R.1672 - Maintaining Investment in New Innovation Act - All Provisions H.R.1492/S.832 - EPIC Act of 2025 - Discussion around encouraging innovation and research transparency for rare disease drugs.

Reported lobbying issue

Health Issues: S. 1973 / H.R. 4231 Treat and Reduce Obesity Act of 2025 S. 864 / H.R. 6423HELP Copays Act H.R.4317 - PBM Reform Act of 2025 COPD awareness/funding Biomarker testing coverage S. 3267 ASAP Act H.R. 3267 Protecting Patient Access to Cancer and Complex Therapies Act

Reported lobbying issue

Health Issues: Prohibiting copay accumulators in ACA Exchange plans: Help Ensure Lower Patient (HELP) Copays Act (H.R. 6423 / S. 864); Transparency and streamline utilization management protocols including prior authorization and step therapy, Safe Step Act, and Improving Senior's Timely Access to Care Act; Increase CMS outreach and education on the Medicare Prescription Payment Program, Increasing Medication Access for Seniors Act (H.R. 6401); Increase participation in clinical trials; Clinical Trials Modernization Act (H.R. 3521 / S. 4440).

Reported lobbying issue

Health Issues: H.R. 2902: SUPPLEMENTAL OXYGEN ACCESS REFORM (SOAR) ACT OF 2025; ALL PROVISIONS H.R. 4317: PHARMACY BENEFIT MANAGER (PBM) REFORM ACT OF 2025; ALL PROVISIONS H.R. 6423: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS H.R. 6837: TO AMEND THE EMPLOYEE RETIREMENT INCOME SECURITY ACT OF 1974 TO ENSURE THAT PHARMACY BENEFIT MANAGERS ARE CONSIDERED FIDUCIARIES, AND FOR OTHER PURPOSES; ALL PROVISIONS H.R 7352: PIONEERING ANTIMICROBIAL SUBSCRIPTIONS TO END UPSURGING RESISTANCE (PASTEUR) ACT OF 2026; ALL PROVISIONS H.R. 7879: SAVING US FROM PANDEMIC ERA RESISTANCE BY BUILDING A UNIFIED GLOBAL STRATEGY (SUPER BUGS) ACT OF 2026; ALL PROVISIONS H.R. 7895: PBM KICKBACK PROHIBITION ACT; ALL PROVISIONS S. 864: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS S. 1406: SUPPLEMENTAL OXYGEN ACCESS REFORM (SOAR) ACT OF 2025; ALL PROVISIONS S. 3549: PBM FIDUCIARY ACCOUNTABILITY, INTEGRITY, AND REFORM (FAIR) ACT S. 4875: PIONEERING ANTIMICROBIAL SUBSCRIPTIONS TO END UPSURGING RESISTANCE (PASTEUR) ACT OF 2026; ALL PROVISIONS GENERAL DISCUSSIONS SURROUNDING ANTIBIOTICS REIMBURSEMENT AND INCENTIVIZING THE DEVELOPMENT OF NOVEL ANTIMICROBIALS GENERAL DISCUSSIONS SURROUNDING MAINTAINING ACCESS TO MEDICAID AND PROPOSED CHANGES TO THE PROGRAM GENERAL DISCUSSIONS ON NEW MEDICAID WORK REPORTING REQUIREMENTS AND DEFINITION OF MEDICAL FRAILTY DESCRIBED IN CMS IFR ON 6/1 GENERAL DISCUSSIONS SURROUNDING NON-COMPREHENSIVE INSURANCE PRODUCTS, EXPANSION OF HDHPS PAIRED WITH HSAS GENERAL DISCUSSION ON ALTERNATIVE FUNDING PROGRAMS (AFPS) GENERAL DISCUSSION ON DRUG PRICING REFORM GENERAL DISCUSSION ON HEALTH COVERAGE REFORM GENERAL DISCUSSIONS SURROUNDING RESTRICTIONS ON ADVANCE FUNDING FOR MULTI-YEAR NIH RESEARCH GRANTS; ISSUES RELATED TO PRESERVING THE SENATES LANGUAGE RESTRICTING ADVANCE FUNDING OF MULTI-YEAR RESEARCH GRANTS BY THE NIH GENERAL DISCUSSIONS PREVENTING FUTURE CUTS TO HEALTHCARE IN POTENTIAL BUDGET RECONCILIATION LEGISLATION CFF COMMENTS ON PRIOR AUTHORIZATION PROPOSED RULE; CFF SUBMITS COMMENTS FOR A PROPOSED RULE ON INTEROPERABILITY AND PRIOR AUTHORIZATION FOR DRUGS AND RELATED RFIS PPC STATEMENT IN RESPONSE TO CMS WORK REPORTING RULE; CFF JOINS PATIENT AND HEALTH GROUPS IN STATEMENT EXPRESSING CONCERN ABOUT THE CMS INTERIM FINAL RULE ON THE MEDICAID WORK CFF SENDS COMMENTS TO DOL ON PBM RULE; CFF SUBMITS COMMENTS TO DOL ON THEIR PROPOSED RULE TO IMPROVE TRANSPARENCY OF PHARMACY BENEFIT MANAGERS Insurance: H.R. 4317: PHARMACY BENEFIT MANAGER (PBM) REFORM ACT OF 2025; ALL PROVISIONS H.R. 6423: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS H.R. 6837: TO AMEND THE EMPLOYEE RETIREMENT INCOME SECURITY ACT OF 1974 TO ENSURE THAT PHARMACY BENEFIT MANAGERS ARE CONSIDERED FIDUCIARIES, AND FOR OTHER PURPOSES; ALL PROVISIONS H.R. 7895: PBM KICKBACK PROHIBITION ACT; ALL PROVISIONS S. 864: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS S. 3549: PBM FIDUCIARY ACCOUNTABILITY, INTEGRITY, AND REFORM (FAIR) ACT GENERAL DISCUSSIONS SURROUNDING MAINTAINING ACCESS TO MEDICAID AND PROPOSED CHANGES TO THE PROGRAM GENERAL DISCUSSIONS ON NEW MEDICAID WORK REPORTING REQUIREMENTS AND DEFINITION OF MEDICAL FRAILTY DESCRIBED IN CMS IFR ON 6/1 GENERAL DISCUSSIONS SURROUNDING NON-COMPREHENSIVE INSURANCE PRODUCTS, EXPANSION OF HDHPS PAIRED WITH HSAS GENERAL DISCUSSION ON ALTERNATIVE FUNDING PROGRAMS (AFPS) GENERAL DISCUSSION ON DRUG PRICING REFORM GENERAL DISCUSSION ON HEALTH COVERAGE REFORM GENERAL DISCUSSIONS SURROUNDING RESTRICTIONS ON ADVANCE FUNDING FOR MULTI-YEAR NIH RESEARCH GRANTS; ISSUES RELATED TO PRESERVING THE SENATES LANGUAGE RESTRICTING ADVANCE FUNDING OF MULTI-YEAR RESEARCH GRANTS BY THE NIH GENERAL DISCUSSIONS PREVENTING FUTURE CUTS TO HEALTHCARE IN POTENTIAL BUDGET RECONCILIATION LEGISLATION CFF COMMENTS ON PRIOR AUTHORIZATION PROPOSED RULE; CFF SUBMITS COMMENTS FOR A PROPOSED RULE ON INTEROPERABILITY AND PRIOR AUTHORIZATION FOR DRUGS AND RELATED RFIS CFF SENDS COMMENTS TO DOL ON PBM RULE; CFF SUBMITS COMMENTS TO DOL ON THEIR PROPOSED RULE TO IMPROVE TRANSPARENCY OF PHARMACY BENEFIT MANAGERS Budget/Appropriations: GENERAL DISCUSSIONS SURROUNDING RESTRICTIONS ON ADVANCE FUNDING FOR MULTI-YEAR NIH RESEARCH GRANTS; ISSUES RELATED TO PRESERVING THE SENATES LANGUAGE RESTRICTING ADVANCE FUNDING OF MULTI-YEAR RESEARCH GRANTS BY THE NIH GENERAL DISCUSSION ON FY2027 APPROPRIATIONS; ISSUES RELATED TO HHS AND RELATED AGENCIES, FDA AND RELATED AGENCIES, CDC AND RELATED AGENCIES, NIH AND RELATED AGENCIES, OBLIGATE STABLE PACE OF SPENDING FY26 FUNDS GENERAL DISCUSSIONS PREVENTING FUTURE CUTS TO HEALTHCARE IN POTENTIAL BUDGET RECONCILIATION LEGISLATION GENERAL DISCUSSION OPPOSING OMBS PROPOSED RULE, REGULATION FOR FEDERAL FINANCIAL ASSISTANCE, RELEASED 5/29 Medical/Disease Research/Clinical Labs: H.R. 2902: SUPPLEMENTAL OXYGEN ACCESS REFORM (SOAR) ACT OF 2025; ALL PROVISIONS H.R 7352: PIONEERING ANTIMICROBIAL SUBSCRIPTIONS TO END UPSURGING RESISTANCE (PASTEUR) ACT OF 2026; ALL PROVISIONS H.R. 7879: SAVING US FROM PANDEMIC ERA RESISTANCE BY BUILDING A UNIFIED GLOBAL STRATEGY (SUPER BUGS) ACT OF 2026; ALL PROVISIONS S. 1406: SUPPLEMENTAL OXYGEN ACCESS REFORM (SOAR) ACT OF 2025; ALL PROVISIONS S. 4875: PIONEERING ANTIMICROBIAL SUBSCRIPTIONS TO END UPSURGING RESISTANCE (PASTEUR) ACT OF 2026; ALL PROVISIONS GENERAL DISCUSSIONS SURROUNDING ANTIBIOTICS REIMBURSEMENT AND INCENTIVIZING THE DEVELOPMENT OF NOVEL ANTIMICROBIALS GENERAL DISCUSSIONS SURROUNDING RESTRICTIONS ON ADVANCE FUNDING FOR MULTI-YEAR NIH RESEARCH GRANTS; ISSUES RELATED TO PRESERVING THE SENATES LANGUAGE RESTRICTING ADVANCE FUNDING OF MULTI-YEAR RESEARCH GRANTS BY THE NIH GENERAL DISCUSSION ON FY2027 APPROPRIATIONS; ISSUES RELATED TO HHS AND RELATED AGENCIES, FDA AND RELATED AGENCIES, CDC AND RELATED AGENCIES, NIH AND RELATED AGENCIES, OBLIGATE STABLE PACE OF SPENDING FY26 FUNDS GENERAL DISCUSSION OPPOSING OMBS PROPOSED RULE, REGULATION FOR FEDERAL FINANCIAL ASSISTANCE, RELEASED 5/29 FOLLOW UP ON ALTERNATIVE FUNDING PROGRAMS AND IMPORTATION OF DRUGS; CFF SENDS LETTER TO FDA AND CDER REGARDING A CITIZEN PETITION CONCERNING ALTERNATIVE FUNDING PROGRAMS (AFPS) COMMENTS ON DRAFT GUIDANCE FOR THE PLAUSIBLE MECHANISM FRAMEWORK; CFF SUBMITS COMMENTS TO THE FDA ON DRAFT GUIDANCE FOR THE PLAUSIBLE MECHANISM FRAMEWORK, URGING A FLEXIBLE APPROACH TO SUPPORT THE DEVELOPMENT OF GENE EDITING AND OTHER THERAPIES FOR PEOPLE WITH ULTRA-RARE MUTATIONS Medicare/Medicaid: GENERAL DISCUSSIONS SURROUNDING MAINTAINING ACCESS TO MEDICAID AND PROPOSED CHANGES TO THE PROGRAM GENERAL DISCUSSIONS ON NEW MEDICAID WORK REPORTING REQUIREMENTS AND DEFINITION OF MEDICAL FRAILTY DESCRIBED IN CMS IFR ON 6/1 GENERAL DISCUSSION ON HEALTH COVERAGE REFORM GENERAL DISCUSSIONS PREVENTING FUTURE CUTS TO HEALTHCARE IN POTENTIAL BUDGET RECONCILIATION LEGISLATION CFF COMMENTS ON PRIOR AUTHORIZATION PROPOSED RULE; CFF SUBMITS COMMENTS FOR A PROPOSED RULE ON INTEROPERABILITY AND PRIOR AUTHORIZATION FOR DRUGS AND RELATED RFIS PPC STATEMENT IN RESPONSE TO CMS WORK REPORTING RULE; CFF JOINS PATIENT AND HEALTH GROUPS IN STATEMENT EXPRESSING CONCERN ABOUT THE CMS INTERIM FINAL RULE ON THE MEDICAID WORK Pharmacy: GENERAL DISCUSSION ON DRUG PRICING REFORM

Reported lobbying issue

Pharmacy: H.R. 5509/S. 2903 - Safe Step Act H.R. 6423/S. 864 - HELP Copays Act H.R. 1189/S. 494 - National Plan for Epilepsy Act Drug Pricing Trade (domestic/foreign): Tariffs

Reported lobbying issue

Medicare/Medicaid: H.R. 3514/S. 1816: Improving Seniors' Timely Access to Care Act of 2025 - requires Medicare Advantage plans to implement electronic prior authorization, increase transparency, protect enrollees, and adhere to new response timeframes to improve timely access to care. H.R. 2433: Reducing Medically Unnecessary Delays in Care Act - mandates that prior authorization decisions under Medicare be made by qualified physicians, based on medical necessity and evidence-based standards, with transparency and input from practicing physicians. S. 1640/H.R. 879: Medicare Patient Access and Practice Stabilization Act of 2025 - This bill increases certain payment adjustments under the Medicare physician fee schedule for services furnished between April 1, 2025, and January 1, 2026. H.R. 8163: Provider Reimbursement Stability Act, to amend title XVIII of the Social Security Act to ensure stability for provider payments under the Medicare program. H.R. 8622: Medicare Physician Data-driven Performance Payment System Act to amend title XVIII of the Social Security Act to transform the Merit-based Incentive Payment System into the Data-driven Performance Payment System under the Medicare physician fee schedule H.R. 6160: Strengthening Medicare for Patients and Providers Act to modify certain adjustments to payment amounts under the Medicare physician fee schedule S. 1460/H.R. 786: Preserving Patient Access to Accountable Care Act - extends Medicare incentive payments for alternative payment models to 2027, with a new rate of 3.53 percent, to promote continued participation and improve healthcare efficiency. H.R. 2120/S. 1031: ROCR Value Based Program Act - establishes a new payment program for radiation oncology services, focusing on stable payments, quality care, and patient access, while exempting it from budget neutrality adjustments. H.R. 4559: Prompt and Fair Pay Act - to establish payment parity between Medicare Advantage and fee-for-service Medicare, and to establish prompt payment requirements under Medicare Advantage. H.R. 2484: Seniors' Access to Critical Medications Act of 2025 - establishes an exception to the physician self-referral prohibition for certain outpatient drugs under Medicare, mandates a study on drug dispensing practices, and reduces the Medicare improvement fund by $18 million. H.R. 4299: Protecting Patient Access to Cancer and Complex Therapies Act - provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation H.R. 4206/S. 1261: CONNECT for Health Act - expands access to telehealth services under Medicare H.R. 5081/S. 2709: Telehealth Modernization Act - to extend certain telehealth flexibilities under the Medicare program. H.R. 4752/S. 2760: Reducing Hereditary Cancer Act - to provide hereditary cancer genetic testing for individuals with a history of a hereditary cancer gene mutation. Health Issues: H.R. 6423/S. 864: HELP Copays Act - requires health insurers to count third-party financial assistance toward patients' cost-sharing obligations, including deductibles and copays, for prescription drugs, with changes effective for plan years beginning January 1, 2026. S. 526: PBM Transparency Act - prevents unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs H.R. 4191/S. 1784: MAPS Act - requires federal agencies to regularly update a list of essential medicines, assess and report on supply chain risks, map pharmaceutical supply chains, and enhance coordination and cybersecurity to protect public health and national security. H.R. 3955/S.2062: RAPID Reserve Act - establishes a $500 million program to create and maintain domestic reserves of critical drugs and their ingredients, prioritizing domestic manufacturing and supply chain resilience to prevent shortages during public health emergencies. H.R. 8339: Drug Origin Transparency Act to amend the Federal Food, Drug, and Cosmetic Act to enhance drug manufacturing amount information reporting H.R. 5526/S. 1954: Biosimilar Red Tape Elimination Act - streamlines the approval process for biosimilar biological products by automatically deeming them interchangeable with reference products, subject to certain exclusivity protections, and requires updated regulatory guidance to reflect these changes. H.R. 4101: Cancer Drug Parity Act of 2025 - requires group health plans to provide cost-sharing for oral anticancer drugs that is at least as favorable as for provider-administered anticancer medications, with protections against increased patient costs and a mandated GAO study on the law's impact. H.R. 3521/S. 4440: Clinical Trials Modernization Act - Increase clinical trial participation among underrepresented populations by providing grants, permitting certain participant reimbursements, and offering tax exclusions, while ensuring compliance with existing legal protections. S. 705: Innovation in Pediatric Drugs Act of 2025 - amends existing laws to enhance pediatric cancer research, mandates compliance measures, allocates funding for pediatric studies, and sets guidelines for orphan drugs, with specific timelines for implementation and evaluation. H.R. 5509/S. 2903: Safe Step Act - to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for any medication step therapy protocol, and for other purposes. H.R. 4425/S. 2287: Palliative Care and Hospice Education and Training Act - expands federal support for workforce development, education, public awareness, and research in palliative and hospice care, with targeted funding and statutory changes to improve care for patients with serious or life-threatening illnesses. H.R. 8839: Lainie Jones Comprehensive Cancer Survivorship Act of 2026 to address the health of cancer survivors. Budget/Appropriations: FY 2026 and FY 2027 Appropriations for the National Institutes of Health (NIH), National Cancer Institute (NCI), the Food & Drug Administration (FDA), the Advanced Research Projects Agency for Health (ARPA-H), the Centers for Disease Control and Prevention (CDC), and the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP).

Reported lobbying issue

Budget/Appropriations: Presidents Budget Fiscal Year 2027 H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 4: Rescissions Act of 2025 (Public Law 119-28) H.R. 4121: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 8646: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 S. ___: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 H. Res. 566: Providing for consideration of the Senate amendment to the bill (H.R. 1) to provide for reconciliation pursuant to title II of H. Con. Res. 14 H.R. 9310: Department of Homeland Security Appropriations Act, 2027 S. 2256: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 S. 2587: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 9260: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 S._____: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 H.R. 5342: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 H.R. 6938: Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriations Act, 2026 (P.L. 119-74) H.R. 8845: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027 S. ___: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027 S. 2354: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 S. 1071: National Defense Authorization Act for Fiscal Year 2026 (Public Law No: 119-60) S. 2296: National Defense Authorization Act for Fiscal Year 2026 H.R. 8800: National Defense Authorization Act for Fiscal Year 2027 S. 4784: National Defense Authorization Act for Fiscal Year 2027 S. 2: Secure America Act (Public Law 119-18) H.R. 7148: Consolidated Appropriations Act, 2026 (Public Law 119-75) Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues Government funding policy issues Copyright/Patent/Trademark: S. 43: Skinny Labels, Big Savings Act S. 1040: Drug Competition Enhancement Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 1546: Patent Eligibility Restoration Act of 2025 (PERA) S. 1553: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) S. 2276: Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 2620: REMEDY Act S. 2658: Medication Affordability and Patent Integrity Act S. 3452: Biological Intellectual Protection Act of 2025 H.R. 890: Stopping Pharmas Ripoffs and Drug Savings For All Act H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) H.R. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) H.R. 4570: Interagency Patent Coordination and Improvement Act of 2025 H.R. 6485: Skinny Labels, Big Savings Act H.R. 6624: Biological Intellectual Property Protection Act of 2025 Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues AI patent policy issues Patent eligibility policy issues Post-grant proceeding policy issues Patent submission policy issues Patent fee policy issues Health Issues: S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 1414: Expedited Access to Biosimilars Act S. 1954: Biosimilar Red Tape Elimination Act S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) S. 2658: Medication Affordability and Patent Integrity Act S. 3014: Ensuring Timely Access to Generics Act of 2025 S. 3345: PBM Price Transparency and Accountability Act S. 3788: CLEAR LABELS Act H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 946: ORPHAN Cures Act H.R. 1262: Mikaela Naylon Give Kids a Chance Act H.R. 1492: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 2214: DRUG Act H.R. 3521: Clinical Trial Modernization Act H.R. 4317: PBM Reform Act of 2025 H.R. 5256: 340B ACCESS Act HR 5509, Safe Step Act, Provisions related step therapy protocols H.R. 6423: HELP Copays Act H.R. 6610: Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act] H.R. 7837: Most Favored Patients Act H.R. 7391, the Community Health Center Drug Pricing Protection Act H.R. 7953: FAIR ACT H.R. 8269: CLEAR LABELS Act Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) 340B Drug Pricing Integrity and Affordability for Patients Act (draft) SECURE Act of 2026 (draft) Biopharmaceutical innovation policy issues User fee issues Vaccine policy issues Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues IRA price negotiation expansion policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Most Favored Nation (MFN) policy issues Drug importation policy issues FDA policy issues Competition policy issues Orphan Drug Act policy issues Antimicrobial resistance policy issues Compounding policy issues Supply chain policy issues Clinical trial policy issues 340B drug discount program rebate and policy issues 340B rebate pilot program Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues Artificial intelligence policy issues Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Executive Order: Lowering Drug Prices by Once Again Putting Americans First S. 891, Bipartisan Health Care Act (including section 227 - Modernizing and Ensuring PBM Accountability) S.4784, An original bill to authorize appropriations for fiscal year 2027 for military activities of the Department of Defense, for military construction, and for defense activities of the Department of Energy, to prescribe military personnel strengths for such fiscal year, and for other purposes, Provisions related to the pharmaceutical industry. Smucker's VICP bill Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) Vaccine policy issues Medicare/Medicaid: H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues Part D redesign and policy issues including non-interference and rebates policy issues Part B policy issues Drug cost and pricing policy issues Medicare rebate policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues CMS IPAY Guidance on the Medicare Drug Price Negotiation Program IPAY and Maximum Fair Prices policy issues Medicaid rebate policy issues GENErating cost Reductions for U.S. Medicaid (GENEROUS) model Global Benchmark for Efficient Drug Pricing (GLOBE) Proposed Rule Guarding U.S. Medicare Against Rising Drugs Costs (GUARD) Proposed Rule Trade (domestic/foreign): Proclamation: Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States (April 2, 2026) S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) H.R. 4780: USTRx Act H.R. 9102: Biotech Investment National Security Act (BINSA) H.R. 9142: Prohibiting Adversarial Patents Act of 2026 (PAPA) Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Tariff policy issues Most Favored Nation (MFN) policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues COINS Act implementation policy issues China outbound investment policy issues including COINS Act US-UK Framework Agreement

Reported lobbying issue

Health Issues: Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, H.R. 6423/S. 864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1 and H.R. 1518 - New Era of Preventing End-Stage Kidney Disease; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments. Medicare/Medicaid: Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals. Taxation/Internal Revenue Code: Corporate tax reform; H.R. 1414 - Cameron's Law, Preservation of Orphan Drug Tax Credit. Budget/Appropriations: Education about non-opioid pain therapies and patient access to non-opioid medicines, updates on coverage progress at the VHA and CMS. Veterans: Issues related to veteran's access to non-opioid alternatives and implementation of report language in the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (PL 119-37). Defense: Issues related to the Defense Health Agency and service member access to non-opioid alternatives, including reinstating the DHA Benefits Advisory Panel and the structured formulary management process. District of Columbia: Issues related to Sec. 232 pharmaceutical tariffs, onshoring active pharmaceutical ingredients (API), and supply chain disruptions for products related to the opioid public health emergency.

Reported lobbying issue

Medicare/Medicaid: Implementation of H.R. 1, One Big Beautiful Bill Act Reimbursement for hemophilia services and treatments in Medicare Reimbursement for hemophilia services and treatments in Medicaid Preserving and expanding access to Medicaid Issues related to 1115 of the Social Security Act; policies related to work requirements in Medicaid Comments on RE: CMS-5545-P: Global Benchmark for Efficient Drug Pricing (GLOBE) Model Comments on CMS-5546-P: Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model Health Issues: Blood and plasma safety and awareness Bleeding disorders awareness Insurance: Implementation of H.R. 1, One Big Beautiful Bill Act Implementation of the Affordable Care Act The HELP Copays Act (S. 864, H.R. 6423) Coverage of hemophilia treatments and services in private insurance plans, including the alternative funding model Policies related to copay accumulator adjustor and maximizer programs Policies related to the extension of enhanced advanced premium tax credits, including HR 247, HR 1, HR 5371, S 46, HR 1834 Comments on Proposed Rule: Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2027; and Basic Health Program (CMS-9883-P) Budget/Appropriations: Funding for federal hemophilia programs in FY26 and FY27 House and Senate Labor-HHS Appropriations bills NIH FY26 and FY27 appropriations Pharmacy: Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing program Medical/Disease Research/Clinical Labs: Hemophilia research, prevention, surveillance and service programs and issues; advancing care for women and girls with bleeding disorders

Reported lobbying issue

Budget/Appropriations: H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 4: Rescissions Act of 2025 (P.L. 119-28) H.R. 3944: Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026 H.R. 4121: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H. Res. 566: Providing for consideration of the Senate amendment to the bill (H.R. 1) to provide for reconciliation pursuant to title II of H. Con. Res. 14 H.R. 4213: Department of Homeland Security Appropriations Act, 2026 S. 2256: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 S. 2587: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5342: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 H.R. 6938: Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriations Act, 2026 (P.L. 119-74) S. 2354: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 H.R. 5371: Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (Public Law 119-37) S. 1071: National Defense Authorization Act for Fiscal Year 2026 (Public Law No: 119-60) S. 2296: National Defense Authorization Act for Fiscal Year 2026 H.R. 7148: Consolidated Appropriations Act, 2026 (Public Law 119-75), Provisions related to the pharmaceutical industry. Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues Government funding policy issues Copyright/Patent/Trademark: S. 43: Skinny Labels, Big Savings Act S. 708: RESTORE Patent Rights Act of 2025 S. 1040: Drug Competition Enhancement Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1546: Patent Eligibility Restoration Act of 2025 (PERA) S. 1553: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) S. 2276: Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 2620: REMEDY Act S. 2658: Medication Affordability and Patent Integrity Act H.R. 1574: RESTORE Patent Rights Act of 2025 H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) H.R. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) H.R. 4570: Interagency Patent Coordination and Improvement Act of 2025 H.R. 6485: Skinny Labels, Big Savings Act Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues AI patent policy issues Patent eligibility policy issues Post-grant proceeding policy issues Patent submission policy issues Patent fee policy issues Health Issues: S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 891: Bipartisan Health Care Act (including section 227 - Modernizing and Ensuring PBM Accountability) S. 932: Give Kids a Chance Act of 2025 S. 1414: Expedited Access to Biosimilars Act S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) S. 2658: Medication Affordability and Patent Integrity Act S. 3345: PBM Price Transparency and Accountability Act S. 3788: CLEAR LABELS Act H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 946: ORPHAN Cures Act H.R. 1262: Mikaela Naylon Give Kids a Chance Act H.R. 1492: H.R. 1492, Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025. To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 2214: DRUG Act H.R. 4317: PBM Reform Act of 2025 H.R. 5256: 340B ACCESS Act H.R. 6423: HELP Copays Act H.R. 7837: Most Favored Patients Act H.R. 7953: FAIR ACT Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) SECURE Act of 2026 (draft) Biopharmaceutical innovation policy issues User fee issues Vaccine policy issues Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues IRA price negotiation expansion policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Most Favored Nation (MFN) policy issues Drug importation policy issues FDA policy issues MAHA Commission Report - Make Our Children Healthy Again Competition policy issues Orphan Drug Act policy issues Antimicrobial resistance policy issues Compounding policy issues Supply chain policy issues Clinical trial policy issues 340B drug discount program rebate and policy issues 340B rebate pilot program Section 340B Public Health Services Act 340B engagement and MFN related engagement Provisions related to the 340B program Patient assistance program policy issues Biosimilar approval and reimbursement policy issues S. 5459: Biosimilars Access and Affordability Act (118th Congress) Drug shortages policy issues Artificial intelligence policy issues Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Executive Order: Lowering Drug Prices by Once Again Putting Americans First Presidential Memoranda: Memorandum for the Secretary of Health and Human Services the Commissioner of Drugs - Addressing Misleading Direct-to-Consumer Prescription Drug Advertisements Biopharmaceutical innovation and pricing issues HR 5509, Safe Step Act, Provisions related step therapy protocols Tariff and MFN issues VICP Bill Medicare/Medicaid: H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) S. 1637: MVP Act Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues Part D redesign and policy issues including non-interference and rebates policy issues Part B policy issues Drug cost and pricing policy issues Medicare rebate policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues CMS IPAY Guidance on the Medicare Drug Price Negotiation Program IPAY and Maximum Fair Prices policy issues Medicaid rebate policy issues GENErating cost Reductions for U.S. Medicaid (GENEROUS) model Global Benchmark for Efficient Drug Pricing (GLOBE) Proposed Rule Guarding U.S. Medicare Against Rising Drugs Costs (GUARD) Proposed Rule Trade (domestic/foreign): S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) H.R. 4780: USTRx Act Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Tariff policy issues Most Favored Nation (MFN) policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues China outbound investment policy issues US-UK Framework Agreement

Reported lobbying issue

Education: -Department of Education, oppose Reductions of Force at and changes to (including moving sections of) the Dept. of Education that could impede the rights of students with disabilities -S. 3448/H.R. 6617, Keeping All Students Safe Act, support passage Budget/Appropriations: -Labor, Health and Human Services, Education and Related Agencies Appropriations Act, 2026, support funding for epilepsy programs and research including $11.581 billion for the CDC including $11.5 million for the CDCs Epilepsy program and $164 million for the CDCs Safe Motherhood and Infant Health Program, at least $48.7 billion for the NIH, $680 million for the BRAIN Initiative, and increased funding for the Social Security Administration. -Labor, Health and Human Services, Education and Related Agencies Appropriations Act, 2027, support funding for epilepsy programs and research including $11.581 billion for the CDC including $11.5 million for the CDCs Epilepsy program and $164 million for the CDCs Safe Motherhood and Infant Health Program; language supporting a report about establishing a National Plan for Epilepsy; at least $51.303 billion for the NIH and $468 million for the BRAIN Initiative; increased funding for the Social Security Administration; and language supporting a report about how the newborn screening evidence-based review process will continue to be implemented and language clarifying that Title V can fund state-sponsored genetic screening pilot programs. -Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2027, support at least $29 million for the VA Epilepsy Centers of Excellence. -Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Act, 2027, support robust funding for the Food & Drug Administration -Defense Appropriations Act, 2026, within the Congressionally Directed Medical Research Programs, support $12 million for the Epilepsy Program, $10 million for the Tuberous Sclerosis Complex program and $175 million for the TBI and Psychological Health Program. -Defense Appropriations Act, 2027, within the Congressionally Directed Medical Research Programs, support $12 million for the Epilepsy Program, $12 million for the Tuberous Sclerosis Complex program and $175 million for the TBI and Psychological Health Program. -Commerce, Justice, Science Appropriations Act, 2026, oppose provisions that could restrict access to CBD and block rescheduling Health Issues: -P.L. 119-21, Support policies and processes that reduce the impact of the cuts and changes to Medicaid on people with serious and chronic conditions, people with disabilities, and caregivers -S. 494/H.R. 1189, National Plan for Epilepsy Act, support passage -Requests to join the Congressional Epilepsy Caucus -S. 2903/H.R. 5509, Safe Step Act, support passage -S. 864/H.R. 6423, HELP Copays Act, support passage -S. 932/ H.R. 1262, Give Kids A Chance Act, support reauthorization of the Rare Pediatric Disease Review Voucher -WISeR Model, express concern with how it could impede access to some epilepsy treatments -PBM Reform, support passage and the inclusion of patient-centric policies -Medicare Part Ds Six Protected Classes policy, support coverage of and access to all epilepsy treatments and express concerns with the impact of the GUARD Model on the Six Protected Classes policy. -Enhanced Advance Premium Tax Credits, support reauthorization. -Medicare Part D out-of-pocket cap and the Medicare Prescription Payment Plan, support patient-centric implementation -ACA marketplace rule, express concerns that changes will decrease enrollment and increase costs -Telehealth, support extensions of telehealth flexibilities including the prescribing of epilepsy medications that are controlled substances -S. 1024/H.R. 2151, Seizure Awareness and Preparedness Act, support passage -S. 752/H.R. 1509, Accelerating Kids Access to Care Act, support passage -U.S. Department of Health and Human Services (HHS), support protecting the current structure of HHS and express concerns with HHS staffing changes and cuts -NIH, support the current structure, current facilities and administrative cost structure, and grantmaking process of the NIH; express concerns with leadership and staffing changes and an expansion of multiyear funding -Support programs that assist caregivers -Oppose legislative or regulatory policies that rely on metrics like Quality-Adjusted Life Years -Support rescheduling and safe and legal access to medical cannabis -S. 1816/ H.R. 3514, Improving Seniors Timely Access to Care Act, support passage -S. 455/H.R. 1061, Protecting Sensitive Locations Act, support passage -Oppose legislation that would weaken the Affordable Care Act protections, including H.R. 2528, Association Health Plans Act and H.R. 2571, Self-Insurance Protection Act -Express concerns with legislative and regulatory policies that would restrict the use of animals in research -Support legislation and policy preserving charitable giving including the Combined Federal Campaign -H.R. 6280, Access to Genetic Counselor Services Act, support passage -Support legislation and regulations that protect Medicaid Home- and Community-Based Services (HCBS) and increase access to these services Civil Rights/Civil Liberties: -FAA reauthorization, support implementation of disability provisions -Surface Transportation Reauthorization, support inclusion of disability and accessibility provisions -Autonomous vehicle legislation, support the inclusion of disability and accessibility provisions

Reported lobbying issue

Budget/Appropriations: H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 4: Rescissions Act of 2025 (Public Law No. 119-28) H.R. 3944: Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026 H.R. 4121: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H. Res. 566: Providing for consideration of the Senate amendment to the bill (H.R. 1) to provide for reconciliation pursuant to title II of H. Con. Res. 14 H.R. 4213: Department of Homeland Security Appropriations Act, 2026 S. 2256: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 S. 2587: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5342: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 H.R. 6938: Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriations Act, 2026 (Public Law No. 119-74) S. 2354: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 H.R. 5371: Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (Public Law No. 119-37) S. 1071: National Defense Authorization Act for Fiscal Year 2026 (Public Law No. 119-60) S. 2296: National Defense Authorization Act for Fiscal Year 2026 H.R. 7148: Consolidated Appropriations Act, 2026 (Public Law 119-75) Inflation Reduction Act of 2022 (Public Law No. 117-169) implementation policy issues Government funding policy issues Copyright/Patent/Trademark: S. 43: Skinny Labels, Big Savings Act S. 708: RESTORE Patent Rights Act of 2025 S. 1040: Drug Competition Enhancement Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 1546: Patent Eligibility Restoration Act of 2025 (PERA) S. 1553: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) S. 2276: Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 2620: REMEDY Act S. 2658: Medication Affordability and Patent Integrity Act H.R. 890: Stopping Pharmas Ripoffs and Drug Savings For All Act H.R. 1574: RESTORE Patent Rights Act of 2025 H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) H.R. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) H.R. 4570: Interagency Patent Coordination and Improvement Act of 2025 H.R. 6485: Skinny Labels, Big Savings Act Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues AI patent policy issues Patent eligibility policy issues Post-grant proceeding policy issues Patent submission policy issues Patent fee policy issues Health Issues: S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 891: Bipartisan Health Care Act (including section 227 - Modernizing and Ensuring PBM Accountability) S. 932: Give Kids a Chance Act of 2025 S. 1414: Expedited Access to Biosimilars Act S. 1954: Biosimilar Red Tape Elimination Act S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) S. 2658: Medication Affordability and Patent Integrity Act S. 3345: PBM Price Transparency and Accountability Act S. 3788: CLEAR LABELS Act H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 946: ORPHAN Cures Act H.R. 1262: Mikaela Naylon Give Kids a Chance Act H.R. 1492: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 2214: DRUG Act H.R. 4317: PBM Reform Act of 2025 H.R. 5256: 340B ACCESS Act H.R. 6423: HELP Copays Act H.R. 7837: Most Favored Patients Act H.R. 7953: FAIR ACT Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) Biopharmaceutical innovation policy issues SECURE Rx Act of 2026 (draft) User fee issues Vaccine policy issues Inflation Reduction Act of 2022 (Public Law No. 117-169) implementation policy issues IRA price negotiation expansion policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Most Favored Nation (MFN) policy issues Drug importation policy issues FDA policy issues MAHA Commission Report - Make Our Children Healthy Again Competition policy issues Orphan Drug Act policy issues Antimicrobial resistance policy issues Compounding policy issues Supply chain policy issues Clinical trial policy issues 340B drug discount program rebate and policy issues 340B rebate pilot program Patient assistance program policy issues Biosimilar approval and reimbursement policy issues S. 5459: Biosimilars Access and Affordability Act (118th Congress) Drug shortages policy issues Artificial intelligence policy issues Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Executive Order: Lowering Drug Prices by Once Again Putting Americans First Presidential Memoranda: Memorandum for the Secretary of Health and Human Services the Commissioner of Drugs - Addressing Misleading Direct-to-Consumer Prescription Drug Advertisements Medicare/Medicaid: H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) S. 1637: MVP Act Inflation Reduction Act of 2022 (Public Law No. 117-169) implementation policy issues Part D redesign and policy issues including non-interference and rebates policy issues Part B policy issues Drug cost and pricing policy issues Medicare rebate policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues CMS IPAY Guidance on the Medicare Drug Price Negotiation Program IPAY and Maximum Fair Prices policy issues Medicaid rebate policy issues GENErating cost Reductions for U.S. Medicaid (GENEROUS) model Global Benchmark for Efficient Drug Pricing (GLOBE) Proposed Rule Guarding U.S. Medicare Against Rising Drugs Costs (GUARD) Proposed Rule Trade (domestic/foreign): S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) H.R. 4780: USTRx Act Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Tariff policy issues Most Favored Nation (MFN) policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues China outbound investment policy issues US-UK Framework Agreement

Reported lobbying issue

Health Issues: H.R. 4317: PHARMACY BENEFIT MANAGER (PBM) REFORM ACT OF 2025; ALL PROVISIONS H.R. 6423: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS H.R 7352: PIONEERING ANTIMICROBIAL SUBSCRIPTIONS TO END UPSURGING RESISTANCE (PASTEUR) ACT OF 2026; ALL PROVISIONS H.R. 7879: SAVING US FROM PANDEMIC ERA RESISTANCE BY BUILDING A UNIFIED GLOBAL STRATEGY (SUPER BUGS) ACT OF 2026; ALL PROVISIONS S. 864: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS GENERAL DISCUSSIONS SURROUNDING ANTIBIOTICS REIMBURSEMENT AND INCENTIVIZING THE DEVELOPMENT OF NOVEL ANTIMICROBIALS GENERAL DISCUSSIONS SURROUNDING THE ENHANCED ADVANCED PREMIUM TAX CREDIT EXPIRATION AND EXTENSION GENERAL DISCUSSIONS SURROUNDING MAINTAINING ACCESS TO MEDICAID AND PROPOSED CHANGES TO THE PROGRAM GENERAL DISCUSSIONS SURROUNDING NON-COMPREHENSIVE INSURANCE PRODUCTS, EXPANSION OF HEALTH DEDUCTIBLE HEALTH PLANS PAIRED WITH HEALTH SPENDING ACCOUNTS GENERAL DISCUSSIONS SURROUNDING FY2026 APPROPRIATIONS; PROVISIONS RELATED TO FUNDING FOR DOMESTIC AND GLOBAL AMR PROGRAMS, PUBLIC HEALTH WORKFORCE REPAYMENT PROGRAM, BIO-PREPAREDNESS WORKFORCE PILOT PROGRAM, AND PROTECTION OF MEDICARE, MEDICAID, AND SOCIAL SECURITY PROGRAMS. HHS AND RELATED AGENCIES STAFFING AND FUNDING, FDA AND RELATED AGENCIES, CDC AND RELATED AGENCIES, NIH AND RELATED AGENCIES, FUNDING FOR NUTRITION ASSISTANCE PROGRAMS, AND MEDICAL EXPENSE DEDUCTION. POLICY RIDERS INCLUDED IN A DRAFT LABOR, HEALTH AND HUMAN SERVICES, AND EDUCATION RELATED AGENCIES FUNDING BILL GENERAL DISCUSSIONS SURROUNDING RESTRICTIONS ON ADVANCE FUNDING FOR MULTI-YEAR NIH RESEARCH GRANTS; PROVISIONS RELATED TO PRESERVING THE SENATES LANGUAGE RESTRICTING ADVANCE FUNDING OF MULTI-YEAR RESEARCH GRANTS BY THE NIH PPC 2027 NOTICE OF BENEFIT AND PAYMENT PARAMETERS; CYSTIC FIBROSIS FOUNDATION JOINS PATIENT AND HEALTH GROUPS IN COMMENTS ON 2027 HHS NOTICE OF BENEFIT AND PAYMENT PARAMETERS PPC LETTER TO CENTERS FOR MEDICARE & MEDICAID SERVICES ON H.R. 1 IMPLEMENTATION; CYSTIC FIBROSIS FOUNDATION JOINS PATIENT AND HEALTH GROUPS IN LETTER TO CMS EXPRESSING CONCERNS AND ASKING FOR FURTHER CLARIFICATION ON PIECES OF H.R. 1 IMPLEMENTATION CYSTIC FIBROSIS FOUNDATION SENDS LETTER TO CENTERS FOR MEDICARE & MEDICAID SERVICES AND CENTER FOR MEDICARE AND MEDICAID INNOVATION; CYSTIC FIBROSIS FOUNDATION SUBMITS COMMENTS TO CMS/CMMI IN RESPONSE TO A PROPOSED MODEL TO ADDRESS DRUG PRICES IN MEDICARE Insurance: H.R. 4317: PHARMACY BENEFIT MANAGER (PBM) REFORM ACT OF 2025; ALL PROVISIONS H.R. 6423: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS S. 864: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS GENERAL DISCUSSIONS SURROUNDING THE ENHANCED ADVANCED PREMIUM TAX CREDIT EXPIRATION AND EXTENSION GENERAL DISCUSSIONS SURROUNDING MAINTAINING ACCESS TO MEDICAID AND PROPOSED CHANGES TO THE PROGRAM GENERAL DISCUSSIONS SURROUNDING NON-COMPREHENSIVE INSURANCE PRODUCTS, EXPANSION OF HEALTH DEDUCTIBLE HEALTH PLANS PAIRED WITH HEALTH SPENDING ACCOUNTS GENERAL DISCUSSIONS SURROUNDING FY2026 APPROPRIATIONS; PROVISIONS RELATED TO FUNDING FOR DOMESTIC AND GLOBAL AMR PROGRAMS, PUBLIC HEALTH WORKFORCE REPAYMENT PROGRAM, BIO-PREPAREDNESS WORKFORCE PILOT PROGRAM, AND PROTECTION OF MEDICARE, MEDICAID, AND SOCIAL SECURITY PROGRAMS. HHS AND RELATED AGENCIES STAFFING AND FUNDING, FDA AND RELATED AGENCIES, CDC AND RELATED AGENCIES, NIH AND RELATED AGENCIES, FUNDING FOR NUTRITION ASSISTANCE PROGRAMS, AND MEDICAL EXPENSE DEDUCTION. POLICY RIDERS INCLUDED IN A DRAFT LABOR, HEALTH AND HUMAN SERVICES, AND EDUCATION RELATED AGENCIES FUNDING BILL GENERAL DISCUSSIONS SURROUNDING RESTRICTIONS ON ADVANCE FUNDING FOR MULTI-YEAR NIH RESEARCH GRANTS; PROVISIONS RELATED TO PRESERVING THE SENATES LANGUAGE RESTRICTING ADVANCE FUNDING OF MULTI-YEAR RESEARCH GRANTS BY THE NIH PPC 2027 NOTICE OF BENEFIT AND PAYMENT PARAMETERS; CYSTIC FIBROSIS FOUNDATION JOINS PATIENT AND HEALTH GROUPS IN COMMENTS ON 2027 HHS NOTICE OF BENEFIT AND PAYMENT PARAMETERS PPC LETTER TO CENTERS FOR MEDICARE & MEDICAID SERVICES ON H.R. 1 IMPLEMENTATION; CYSTIC FIBROSIS FOUNDATION JOINS PATIENT AND HEALTH GROUPS IN LETTER TO CMS EXPRESSING CONCERNS AND ASKING FOR FURTHER CLARIFICATION ON PIECES OF H.R. 1 IMPLEMENTATION Budget/Appropriations: GENERAL DISCUSSIONS SURROUNDING FY2026 APPROPRIATIONS; PROVISIONS RELATED TO FUNDING FOR DOMESTIC AND GLOBAL AMR PROGRAMS, PUBLIC HEALTH WORKFORCE REPAYMENT PROGRAM, BIO-PREPAREDNESS WORKFORCE PILOT PROGRAM, AND PROTECTION OF MEDICARE, MEDICAID, AND SOCIAL SECURITY PROGRAMS. HHS AND RELATED AGENCIES STAFFING AND FUNDING, FDA AND RELATED AGENCIES, CDC AND RELATED AGENCIES, NIH AND RELATED AGENCIES, FUNDING FOR NUTRITION ASSISTANCE PROGRAMS, AND MEDICAL EXPENSE DEDUCTION. POLICY RIDERS INCLUDED IN A DRAFT LABOR, HEALTH AND HUMAN SERVICES, AND EDUCATION RELATED AGENCIES FUNDING BILL GENERAL DISCUSSIONS SURROUNDING RESTRICTIONS ON ADVANCE FUNDING FOR MULTI-YEAR NIH RESEARCH GRANTS; PROVISIONS RELATED TO PRESERVING THE SENATES LANGUAGE RESTRICTING ADVANCE FUNDING OF MULTI-YEAR RESEARCH GRANTS BY THE NIH GENERAL DISCUSSIONS SURROUNDING FY2027 APPROPRIATIONS; PROVISIONS RELATED TO NATIONAL INSTITUTE OF HEALTH AND FOOD AND DRUG ADMINISTRATION Medical/Disease Research/Clinical Labs: H.R 7352: PIONEERING ANTIMICROBIAL SUBSCRIPTIONS TO END UPSURGING RESISTANCE (PASTEUR) ACT OF 2026; ALL PROVISIONS H.R. 7879: SAVING US FROM PANDEMIC ERA RESISTANCE BY BUILDING A UNIFIED GLOBAL STRATEGY (SUPER BUGS) ACT OF 2026; ALL PROVISIONS GENERAL DISCUSSIONS SURROUNDING ANTIBIOTICS REIMBURSEMENT AND INCENTIVIZING THE DEVELOPMENT OF NOVEL ANTIMICROBIALS GENERAL DISCUSSIONS SURROUNDING MAINTAINING ACCESS TO MEDICAID AND PROPOSED CHANGES TO THE PROGRAM GENERAL DISCUSSIONS SURROUNDING FY2026 APPROPRIATIONS; PROVISIONS RELATED TO FUNDING FOR DOMESTIC AND GLOBAL AMR PROGRAMS, PUBLIC HEALTH WORKFORCE REPAYMENT PROGRAM, BIO-PREPAREDNESS WORKFORCE PILOT PROGRAM, AND PROTECTION OF MEDICARE, MEDICAID, AND SOCIAL SECURITY PROGRAMS. HHS AND RELATED AGENCIES STAFFING AND FUNDING, FDA AND RELATED AGENCIES, CDC AND RELATED AGENCIES, NIH AND RELATED AGENCIES, FUNDING FOR NUTRITION ASSISTANCE PROGRAMS, AND MEDICAL EXPENSE DEDUCTION. POLICY RIDERS INCLUDED IN A DRAFT LABOR, HEALTH AND HUMAN SERVICES, AND EDUCATION RELATED AGENCIES FUNDING BILL GENERAL DISCUSSIONS SURROUNDING RESTRICTIONS ON ADVANCE FUNDING FOR MULTI-YEAR NIH RESEARCH GRANTS; PROVISIONS RELATED TO PRESERVING THE SENATES LANGUAGE RESTRICTING ADVANCE FUNDING OF MULTI-YEAR RESEARCH GRANTS BY THE NIH GENERAL DISCUSSIONS SURROUNDING FY2027 APPROPRIATIONS; PROVISIONS RELATED TO NATIONAL INSTITUTE OF HEALTH AND FOOD AND DRUG ADMINISTRATION CYSTIC FIBROSIS FOUNDATION SENDS LETTER TO CENTERS FOR MEDICARE & MEDICAID SERVICES AND CENTER FOR MEDICARE AND MEDICAID INNOVATION; CYSTIC FIBROSIS FOUNDATION SUBMITS COMMENTS TO CMS/CMMI IN RESPONSE TO A PROPOSED MODEL TO ADDRESS DRUG PRICES IN MEDICARE Medicare/Medicaid: GENERAL DISCUSSIONS SURROUNDING MAINTAINING ACCESS TO MEDICAID AND PROPOSED CHANGES TO THE PROGRAM GENERAL DISCUSSIONS SURROUNDING FY2026 APPROPRIATIONS; PROVISIONS RELATED TO FUNDING FOR DOMESTIC AND GLOBAL AMR PROGRAMS, PUBLIC HEALTH WORKFORCE REPAYMENT PROGRAM, BIO-PREPAREDNESS WORKFORCE PILOT PROGRAM, AND PROTECTION OF MEDICARE, MEDICAID, AND SOCIAL SECURITY PROGRAMS. HHS AND RELATED AGENCIES STAFFING AND FUNDING, FDA AND RELATED AGENCIES, CDC AND RELATED AGENCIES, NIH AND RELATED AGENCIES, FUNDING FOR NUTRITION ASSISTANCE PROGRAMS, AND MEDICAL EXPENSE DEDUCTION. POLICY RIDERS INCLUDED IN A DRAFT LABOR, HEALTH AND HUMAN SERVICES, AND EDUCATION RELATED AGENCIES FUNDING BILL PPC 2027 NOTICE OF BENEFIT AND PAYMENT PARAMETERS; CYSTIC FIBROSIS FOUNDATION JOINS PATIENT AND HEALTH GROUPS IN COMMENTS ON 2027 HHS NOTICE OF BENEFIT AND PAYMENT PARAMETERS PPC LETTER TO CENTERS FOR MEDICARE & MEDICAID SERVICES ON H.R. 1 IMPLEMENTATION; CYSTIC FIBROSIS FOUNDATION JOINS PATIENT AND HEALTH GROUPS IN LETTER TO CMS EXPRESSING CONCERNS AND ASKING FOR FURTHER CLARIFICATION ON PIECES OF H.R. 1 IMPLEMENTATION CYSTIC FIBROSIS FOUNDATION SENDS LETTER TO CENTERS FOR MEDICARE & MEDICAID SERVICES AND CENTER FOR MEDICARE AND MEDICAID INNOVATION; CYSTIC FIBROSIS FOUNDATION SUBMITS COMMENTS TO CMS/CMMI IN RESPONSE TO A PROPOSED MODEL TO ADDRESS DRUG PRICES IN MEDICARE

Reported lobbying issue

Health Issues: Access to Care One Big Beautiful Bill, P.L. 119-21. Advocate to protect cancer patients in implementation of changes to Medicaid under the law. Health Care Affordability Act, H.R.247, S.46. Bill would permanently extend the enhanced Affordable Care Act tax credits. Association Health Plans Act, H.R.2528, S.1847. This bill would amend the Employee Retirement Income Security Act of 1974 to treat association health plans as employers. Self-Insurance Protection Act, H.R. 2571. This bill would amend the Employee Retirement Income Security Act of 1974 to exclude from the definition of health insurance coverage certain medical stop-loss insurance. Access to Breast Cancer Diagnosis Act, H.R. 3037/S.1500. To amend title XXVII of the Public Health Service Act to prohibit group health plans and health insurance issuers offering group or individual health insurance coverage from imposing cost-sharing requirements with respect to diagnostic and supplemental breast examinations. Women and Lung Cancer Research and Preventative Services Act of 2025, H.R.2319, S.1157. This bill requires the Department of Health and Human Services working with the Department of Defense, to conduct an interagency review to evaluate the status of and identify opportunities for research on women and lunch cancer preventative services. Safe Step Act, H.R. 5509, S. 2903. Bill would require an exceptions process for any medication step therapy protocol in commercial insurance plans. Bipartisan Premium Tax Credit Extension Act, H.R. 5145, Bill would extend the enhanced ACA tax credits for one year. Breaking the Gridlock Act, H.R. 1834. Bill would extend the enhanced Affordable Care Act tax credits for three years. Common Ground for Affordable Health Care Act, H.R.6575. Bill would extend the enhanced Affordable Care Act tax credits for one year and make other adjustments. Bipartisan Health Insurance Affordability Act, H.R.6501. Bill would extend the enhanced Affordable Care Act tax credits for two years and make other adjustments. Medically Tailored Home-Delivered Meals Demonstration Pilot Act, H.R.5439, S.2834. The bill would create a pilot program in Medicare for beneficiaries with diet-related diseases to receive medically tailored meals to their own home. Womens Health and Cancer Rights Modernization Act of 2025, H.R.5813. This bill amends the Womens Health & Cancer Rights Act to require that commercial health plans provide coverage of breast or wall reconstruction provided as part of breast cancer treatment. HELP Copays Act, H.R. 6423, S. 864. Bill would apply financial assistance towards the cost-sharing requirements of health insurance plans. Health Disparities Nancy Gardner Sewell Medicare Early Detection Screening Coverage Act, P.L. 119-75. Legislation to improve access to new and innovative cancer screenings for Medicare beneficiaries by creating a pathway to allow Medicare to initiate coverage of multi-cancer tests following FDA approval if a clinical benefit is shown. Screening for Communities to Receive Early and Equitable Needed Services (SCREENS for Cancer Act, H.R. 2381, S.1866. Reauthorizes the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) through 2030 to provide the program greater flexibility in providing access to lifesaving screening, diagnostic, and treatment services and continue its innovative work aimed to reduce disparities and advance health equity in breast and cervical cancer. Education and Awareness Requires Learning Young (EARLY) Act, H.R. 4541, S. 2339. This bill would reauthorize the CDC program that supports young and high-risk women as well as their providers to better understand breast health. Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act, H.R. 1300, S. 297. Legislation to remove cost sharing of PSA testing for those at the highest risk of being diagnosed with prostate cancer. Lung Cancer Screening and Prevention Act, H.R.1406. To amend title XVIII of the Social Security Act to authorize the coverage of additional lung cancer screening tests under the Medicare program. Data Equity. Legislative and regulatory funding to support the collection of detailed demographic data toward reducing disparities in cancer prevention, detection, and treatment. Prevent HPV Cancer Act of 2025, H.R. 6561. This bill would create a national public awareness campaign to promote education and awareness of HPV and HPV-associated cancers and would increase funding for the NBCCED program to boost breast and cervical cancer screening. Childhood Cancer Childhood Cancer Survivorship, Treatment, Access, and Research Reauthorization Act (STAR) Act. Continued implementation and funding of the Childhood Cancer STAR Act to promote the development of new, safer therapies for children with cancer. Our appropriations request includes $30 million for the Childhood Cancer STAR Act and $50 million for the Childhood Cancer Data Initiative. Accelerating Kids Access to Care Act, P.L. 119-75. Legislation that alleviates these burdens for families and providers by facilitating coordination across state lines and clarifying the process by which state Medicaid programs can cover specialized treatment regardless of where the child lives and where their care is received. Give Kids and Chance Act of 2025, P.L. 119-75. Legislation that would accelerate pediatric cancer treatments and expand access to live-saving therapies for children battling rare diseases, spur drug development for pediatric rare diseases, improve outcomes for patients, and close gaps in pediatric drug research. One Big Beautiful Bill, P.L. 119-21, Advocate to protect pediatric cancer patients in implementation of changes to Medicaid under the law. Quality of Life Palliative Care Palliative Care and Hospice Education and Training Act (PCHETA), S. 22870, H.R. 4425. Legislation to facilitate access to palliative care and coordinated care management. Palliative Care Research Funding. Funding to focus and expand national research programs in palliative care at the National Institutes of Health. Specifically, ACS CAN is working to include funding for palliative care research in the FY26 LHHS Appropriations bill. Federal Health Care Programs Department of Defense Cancer Research Funding. Ensure continued funding for cancer research within the DOD's Congressionally Directed Medical Research Program. Clinical Trials Clinical Trial Modernization Act, H.R. 3521. Increase access to clinical trials for all persons with cancer to participate by reducing barriers to enrollment including support for and remote access to trials. To amend the Internal Revenue Act of 1986 to exclude from gross income certain compensation to clinical trial participants, and for other purposes, H.R. 4184. Legislation to amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants. Taxation/Internal Revenue Code: One Big Beautiful Bill Act, P.L.119-21. Advocate to protect cancer patients in implementation of changes to Medicaid under the law. Issues regarding expanding the availability of the charitable deduction for non-itemizers. Issues respecting charitable giving and life income planning, issues regarding taxation of charitable organizations, and issues regarding economic relief for nonprofit organizations. Issues related to stimulus for nonprofit organizations and increasing charitable giving. Clinical Trial Modernization Act, H.R. 3521. Increase access to clinical trials for all persons with cancer to participate by reducing barriers to enrollment including support for ancillary (non-medical) costs and remote access to trials. To amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants, and for other purposes, H.R. 4184. Legislation to amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants. Health Care Affordability Act, H.R. 247, S. 46. Bill would permanently extend the enhanced Affordable Care Act tax credits. Bipartisan Premium Tax Credit Extension Act, H.R. 5145. Bill would extend the enhanced ACA tax credits for one year. Breaking the Gridlock Act, H.R. 1834. Bill would extend the enhanced Affordable Care Act tax credits for three years. CommonGround for Affordable Health Care Act, H.R.6575. Bill would extend the enhanced Affordable Care Act tax credits for one year and make other adjustments. Bipartisan Health Insurance Affordability Act, H.R.6501. Bill would extend the enhanced Affordable Care Act tax credits for two years and make other adjustments. A bill to amend the Internal Revenue Code of 1986 to extend the temporary enhanced premium credits, S.2824. Bill would extend the enhanced ACA tax credits for two years. Tobacco: Issues relating to smoking cessation, age of sale of tobacco products, tobacco taxes, graphic warning labels, product regulation, and smoke-free environments.; Issues relating to FDA regulation of flavors, electronic cigarettes and cigars. Strengthening Task Force Operations to Prevent Illicit Vaping Act (STOP Illicit Vaping Act), H.R.6845, / S.3569, Bill would codify and strengthen the federal multi-agency task force, led by the Department of Justice and Food and Drug Administration, to coordinate enforcement, information sharing, and strategy to combat the illegal importation, distribution, and sale of unauthorized e-cigarettes. Increasing Access to Lung Cancer Screening Act, H.R.6178. This legislation provides coverage without cost-sharing for lung cancer screening and tobacco cessation to those on Medicaid and codifies existing lung cancer screening requirements and eliminates prior authorization for those on Medicare and private insurance. Helping Tobacco Users Quit Act, S. 2064. This bill provides for coverage of certain tobacco cessation services, without cost-sharing, of diagnostic, therapy, and counseling services and pharmacotherapy, including prescription and nonprescription tobacco cessation agents, that are provided under medical supervision and in accordance with specified guidelines under Medicaid and Children's Health Insurance Program (CHIP). Budget/Appropriations: One Big Beautiful Bill Act, P.L.119-21. Advocate to protect cancer patients in implementation of changes to Medicaid under the law. FY26 Labor, Health, and Human Services funding provisions. ACS CAN advocated for full implementation of the law and for funding to be issued consistent with statute. FY27 House and Senate Labor, Health and Human Services legislation. ACS CAN advocates for increases in cancer research and prevention, including NIH, NCI, CDC DCPC, and OSH funding. FY25 Defense Appropriations for cancer programs with CDMRP. ACS CAN advocates for cancer research funding within CDMRP and funding for the Initiative for Improving Native American Cancer Outcomes through NCIs coordination with NIMHD. FY27 Defense Appropriations for cancer programs with CDMRP. ACS CAN advocates for cancer research funding within CDMRP. ACS CAN advocates for increases in programs that advance research for cancers include the Peer Reviewed Cancer Research Program (PRCRP). FY27 Interior Appropriations for Indian Health Services funding. ACS CAN advocates for increased funding for health with a focus on cancer funding. FY27 Agriculture and FDA Appropriations for issues related to drug shortages and tobacco. ACS CAN advocates for funding for the FDA, for provisions to address drug shortages, and on tobacco policy including issues related to the FDA regulation of flavors, electronic cigarettes, and cigars and cessation therapies as well as language to reduce drug shortages and fully implement FDORA. Indian Programs Advance Appropriations Act of 2025, S. 2771, H.R. 5328. The bill would provide advance appropriations authority for certain accounts of the Bureau of Indian Affairs and Bureau of Indian Education of the Department of the Interior and the Indian Health Service. Medicare/Medicaid: One Big Beautiful Bill Act, P.L.119-21. Advocate to protect cancer patients in implementation of changes to Medicaid under the law. Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act, P.L. 119-75. Legislation to improve access to new and innovative cancer screenings for Medicare beneficiaries by creating a pathway to allow Medicare to initiate coverage of multi-cancer tests following FDA approval if a clinical benefit is shown. Lung Cancer Screening and Prevention Act, H.R. 140. To amend title XVIII of the Social Security Act to authorize the coverage of additional lung cancer screening tests under the Medicare program. Accelerating Kids Access to Care Act, P.L. 119-75. Legislation that alleviates these burdens for families and providers by facilitating coordination across state lines and clarifying the process by which state Medicaid programs can cover specialized treatment regardless of where the child lives and where their care is received. Ensuring Access to Essential Providers Act, S.2793. Bill would require Medicare Advantage plans to cover items and services furnished by certain essential community providers. Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, H.R. 5269, S. 2761. Bill would address Medicare reimbursement of laboratory services. Access to Genetic Counselor Services Act, H.R.6280. Bill would expand coverage of genetic counseling services under Medicare. Lung Cancer Screening and Prevention Act of 2025, H.R. 1406. This bill authorizes Medicare coverage of additional types of lung cancer screening tests that are approved by the FDA, regardless of whether they are recommended by the United States Preventive Services Task Force (USPSTF). Increasing Access to Lung Cancer Screening Act, H.R.6178. This legislation provides coverage without cost-sharing for lung cancer screening and tobacco cessation to those on Medicaid and codifies existing lung cancer screening requirements and eliminates prior authorization for those on Medicare and private insurance. Medical/Disease Research/Clinical Labs: Clinical Trial Modernization Act, H.R. 3521. Increase access to clinical trials for all persons with cancer to participate by reducing barriers to enrollment, including support for ancillary (non-medical) costs. To amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants, and for other purposes, H.R. 4184. Legislation to amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants. Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, H.R. 5269, S. 2761. Bill would address Medicare reimbursement of laboratory services. Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act, P.L. 119-75. Legislation to improve access to new and innovative cancer screenings for Medicare beneficiaries by creating a pathway to allow Medicare to initiate coverage of multi-cancer tests following FDA approval if a clinical benefit is shown. Defense: Defense Appropriations. ACS CAN advocates for cancer research funding within CDMRP. Indian/Native American Affairs: Issues relating to Indian Health Services and the Congressional Native American Caucus. FY27 appropriations for the Indian Health Service. ACS CAN advocates for full funding for FY27 and advanced appropriations to ensure American Indians and Alaska Natives have access to quality and affordable health care services. Indian Programs Advance Appropriations Act of 2025, S. 2771, H.R. 5328. The bill would provide advance appropriations authority for certain accounts of the Bureau of Indian Affairs and Bureau of Indian Education of the Department of the Interior and the Indian Health Service. FY27 appropriations for the Initiative for Improving Native American Cancer Outcomes under the NIMHD and NCI. ACS CAN advocates for the continuation of full funding for the program to support research, education, outreach, and clinical access related to cancer in Native American populations.